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1.1 MULTIPLE MYELOMA
 Multiple Myeloma (MM) is a malignant plasma cell disorder which accounts for 
approximately 10% of the malignant hematologic neoplasms(1, 2). In the pathophysiology 
of MM, the interaction between myeloma cells and the bone marrow microenvironment 
leads to a complex signalling network that sustains survival of the malignant cell and mediates 
tumour progression and drug resistance. Major signalling pathways involved are the IL-6R/
STAT3, Ras/MAPK, PI3K/Akt, notch, WNT- and NF-κB pathways(3). The cytokine 
interleukin-6 is presumed to play a pivotal role in the pathogenesis and malignant growth 
of MM(4) and IL-6 levels are elevated in case of active disease(5). IL-6 also plays a 
stimulatory role in the coagulation mechanism(6). It has been shown to promote the 
transcription of the factor VIII gene(7), decrease protein S levels in canine models(8), induce 
ultra large and hyperreactive von Willebrand Factor(9), and inhibit the cleavage of ultra large 
von Willebrand Factor(6). 
 In search for the optimal treatment for MM, many regimens have been introduced 
during the past twenty years resulting ultimately in a significant improvement in 
survival(10). The first standard of care was a melphalan/prednison based regimen with 
complete remission rates of less than five percent. In the early eighties, high dose melphalan 
was introduced in combination with autologous stem cell infusion support(11). This 
resulted in a complete remission rate of up to 50 percent and a moderate increase in mean 
overall survival of less than three years to nearly 5 years. The high dose melphalan was 
usually preceded by multi-agent chemotherapy such as vincristin, doxorubicine and 
dexamethason (VAD) to reduce tumor burden. In search for newer strategies and therapy 
regimens, thalidomide was introduced, due to its anti-angiogenic effect, and exhibited 
exciting responses in refractory and/or relapsed MM(12, 13). The most recently developed 
and introduced treatment is the proteasome inhibitor Bortezomib(14). Bortezomib was 
introduced as a second or third line treatment option in refractory and or relapsed MM. 
Currently this drugs is investigated in the upfront setting in clinical trials. Novel agents 
including lenalidomide and anti interleukin-6 antibodies are also currently under 
investigation in MM. 
 The current standard of care for younger patients (<65years of age) with MM who are 
in good performance status is combination chemotherapy using non-alkylator-containing 
regimens such as VAD as an induction therapy followed by high dose melphalan in 
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combination with autologous stem-cell transplantation(15). VAD induction courses are now 
preferred over regimens containing melphalan because they are less toxic to bone marrow 
stem cells and allow stemcell harvesting prior to high dose therapy. Recently also 
thalidomide containing induction regimens have been introduced (thalidomide, doxorubicin 
and dexamethason: TAD). Patients treated for MM may encounter significant toxicity such 
as (catheter related) infection, sepsis and venous thrombosis. Especially doxorubicin 
containing chemotherapy regimens in combination with thalidomide have been shown to 
enhance the risk of venous thrombo-embolic events(16). 
1.2 MALIGNANCY AND VENOUS THROMBOEMBOLISM
 Deep vein thrombosis (DVT) and pulmonary embolism (PE), are manifestations of 
venous thromboembolism (VTE). The annual age- and sex-adjusted incidence of VTE in the 
general population, is 10/00, including 0.50/00 for DVT and 0.70/00 for PE(17). In cancer pa-
tients, the incidence is more than 7% with certain cancers even having a significantly higher 
risk of VTE (18). Factors that increase this risk include high age, recent surgery, recent trau-
ma, hormonal therapy and long periods of immobility(19). The French physician 
Armand Trousseau was the first to recognize the association between malignancy and 
VTE(19). In patients with overt cancer, spontaneous venous thrombosis, thromboembolism 
after cancer surgery, thromboembolism during chemotherapy and thrombosis of central 
venous access lines occur in 10-15% as clinical manifestations of thrombosis(20). Advanced 
tumour stage, conventional chemotherapy, and immunomodulators in combination with 
chemotherapy increase the risk of VTE in cancer patients(21-23). Overall, cancer increases 
the risk of thrombosis more than four-fold and chemotherapy 6.5-fold(21).
 Hereditary risk factors for VTE include the factor V Leiden mutation and the 
prothrombin 20210A mutation. In the general population the factor V Leiden mutation 
increases the risk of VTE by 3-8 fold(24). In cancer patients who are carriers of the factor V 
Leiden mutation the risk of VTE is increased to 12-fold compared to non cancer patients 
who are carriers(25). The protrombin 20210A mutation increases the risk of VTE 
approximately two-fold in the general population(26) and in cancer patients this mutation 
increases the risk of VTE similar to that seen in cancer patients with the factor V Leiden 
mutation(25). 
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1.3 INCIDENCE OF THROMBO-EMBOLIC COMPLICATIONS 
IN MULTIPLE MYELOMA
 The first report regarding an increased incidence of VTE during or shortly after 
multi-agent chemotherapy in patients with newly diagnosed MM dates from 1999(27). In 
this report a VTE incidence of 10% was reported in newly diagnosed patients receiving VAD 
or high dose cyclophosphamide as induction chemotherapy to reduce tumour burden(27). 
Since then, many reports regarding the incidence of thrombo-embolic complications in 
patients with either newly diagnosed, refractory or relapsed MM have been reported 
(summarized in Table 1, 2a and 2b). 
 Among the reported VTE complications DVT of the lower extremity is the most 
frequent occurring events. Less frequently observed are central venous catheter-related 
thrombosis, pulmonary embolism and venous thrombosis of the arm(28, 29). More rarely 
observed thrombotic complications concern arterial thrombosis including myocardial 
infarction, intestinal ischemia, and ischemic stroke(30-32). 
 The incidence of VTE varies between the different regimens used to treat MM. Oral 
therapy with melphalan and prednisone (MP) is associated with the lowest incidence of VTE 
of 0-2%(31, 33). Thalidomide, an immunomodulatory drug, used as a single agent, is 
associated with a similar incidence of VTE of 2%(34). However, thalidomide in combination 
with dexamethasone only or in combination with cytotoxic chemotherapy regimens, 
increases the risk of VTE significantly(35). The combination of thalidomide and 
dexamethasone (thal/dex) seems to be associated with a VTE incidence of 7-26%(1, 13, 
36-42). When combined with the oral MP regimen (MPT), incidences of 12-16% are 
reported in elderly patients(31, 43). The VTE incidence during regimens combining 
thalidomide with antracyclines based cytotoxic chemotherapy regimens ranges from 
10-35%(16, 28, 44-51). Lenalidomide is a new immunomodulatory drug with a similar 
structure to thalidomide but functionally distinct. In a multicenter phase 3 trial in relapsed/
refractory MM patients, thromboembolic events were reported in 4.5% and when 
lenalidomide was combined with dexamethasone this incidence increases to 8.5%(52). The 
recently introduced proteasome inhibitor Bortezomib seems to be less thrombogenic and 
up till now the reported incidence of thrombo-embolic complications remains low (0-1%), 
even when used in combination with dexamethasone(53-55). 
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1.4 HEMOSTATIC ABNORMALITIES IN MULTIPLE MYELOMA
 The development of a thrombus depends on three elements which were first described 
by Virchow over 150 years ago (Virchow’s triad)(66). These elements include stasis and 
reduced blood flow, abnormal blood coagulability and an altered blood vessel wall. The 
formation of a thrombus depends on the primary- and secondary haemostatic system. In 
the primary haemostasis circulating platelets interact with activated endothelial cells or the 
subendothelial matrix to form mural thrombi. The interaction of platelet GPIbα or GPVI 
with von Willebrand factor (vWF) and collagen, initiates activation of integrin αIIbβ3 that 
binds von Willebrand factor and fibrinogen. This eventually results in platelet-platelet 
interaction and platelet aggregation, finally resulting in the formation of a platelet plug 
(Figure 1)(67, 68). 
figure 1. Primary haemostatic system.When the vessel wall is intact, plasma von Willebrand factor (vWF) that is 
present in a coiled structure and platelets coexist in circulating blood with minimal interactions (Panel A). In the 
damaged vessel wall (Panel B), collagen of the subendothelial matrix becomes exposed and binds to plasma von 
Willebrand factor which than uncoils and supports the adhesion of platelets and promote platelet adhesion and 
activation through a stepwise proces. This allows plates to bind to the vessel wall and forms a platelet plug (Panel C).
A
Platelet
Collagen
Plasma
vWF
Endothelial cell
Activated
Platelet
B
Platelet plug
C
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Secondary hemostasis is initiated by Tissue Factor (TF) and proceeds through a stepwise 
activation of proteases that eventually results in a fibrin network which stabilises the platelet 
plug and forms a thrombus (Figure 2)(69). 
  In this cascade, tissue factor expression is a critical step in the initial formation of fibrin. 
The formation of the clot is highly regulated by natural anticoagulant mechanisms such as 
antithrombin, the protein C system and the fibrinolytic system. It is well established that 
patients with malignancy have a high risk of VTE which is suggested to be a result of an 
altered balance between the coagulation and fibrinolytic systems resulting in a prothrom-
botic or hypercoagulable state(70). In patients with malignancy, also other factors may in-
crease the risk of thrombosis, including the use of central venous catheters, immobilisation 
and infections. 
 Well known additional risk factors for thrombo-embolic complications specifically 
encountered in patients with MM include increased age, use of anti-angiogenic drugs in 
combination with chemotherapy, and high levels of acute phase proteins(71). Recently, in 
TF-VIIa
TF pathway
inhibitor
Xa + Va Thrombin
Fibrin
Fibrinolysis
Antithrombin
Thrombin
activatable
fibrinolysis
inhibitor
(TAFI)
Plasmin
Thrombomodulin
Activated
Protein C + Protein S
IXa + VIIIa
XIa
Fibrinogen
figure 2. Secondary haemostatic system, inhibition (-------), activation (______). Plasmin induces the breakdown 
of fibrinogen.
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MM, new acquired coagulation changes have been identified that are associated with a 
hypercoagulable state. These changes involve factors that are related to both primary and 
secondary hemostasis such as increased FVIII levels and vWF levels and acquired resistance 
to activated protein C (APC)(35, 46, 72). 
 Most thrombo-embolic episodes are observed in the early course of treatment and it 
has been suggested that they may be related to a high tumor load(73). Furthermore, the 
release of inflammatory cytokines, especially interleukin (IL)-6, which plays a pivotal role in 
MM, may alter the coagulation mechanism into a hypercoagulable state(74). In contrast, 
inherited thrombophilic factors, including Factor V-Leiden mutation and the prothrombin 
gene mutation, seem to play only a marginal role(75).
1.5 PREVENTING THROMBO-EMBOLIC COMPLICATIONS IN 
MULTIPLE MYELOMA
 The recognition of a hypercoagulable state in newly diagnosed MM, especially during 
multi-agent chemotherapy in combination with anti-angiogenic drug, has led to the 
introduction of prophylactic anticoagulant therapy. The use of either low molecular weight 
heparin or full-intensity warfarin (target INR: 2-3) has been shown to reduce the risk of 
thrombo-embolic complications(29, 76). A fixed low dose of warfarin however, seems to 
reduce this risk insufficiently(16). The use of a fixed low-dose aspirin as thrombo-phophylaxis 
in clinical trials has also been shown to reduce the incidence of venous thromboembolism 
in MM(77). The optimal antithrombotic regime in MM patients receiving induction treatment 
has yet to be established and is currently under investigation(78). 
1.6 AIMS AND OUTLINE OF THE THESIS
As previously described, patients with untreated MM exhibit a hypercoagulable state which 
makes these patients susceptible to thrombo-embolic complications. Although some 
coagulation abnormalities have been reported in the literature, there are still many 
questions left unanswered and the mechanism of VTE in MM is still not yet fully 
understood. Therefore we initiated several studies to increase our knowledge regarding the 
hypercoagulable state in patients with MM. 
20
 Since most thromboembolic complications in untreated MM patients are observed 
during the induction phase of treatment, our first aim is to study the presence of 
coagulation abnormalities in patients with newly diagnosed MM who are eligible for 
intensive multi-agent chemotherapy (chapter 2). Both the primary and the secondary 
hemostasis-related coagulation factors are determined prior to the start of intensive 
cytoreductive chemotherapy. 
 The second aim of the study is to monitor the disorders in the coagulation system 
during and after intensive chemotherapy. For this, we determined the plasma levels of 
various coagulation factors at start of treatment and at several time points during and after 
chemotherapy (chapter 3). 
 Our third aim is to investigate the fibrinolytic system in these patients and determine 
alterations of fibrinolysis during treatment, since hypofibrinolysis is known to be associated 
with venous thrombosis (chapter 4). 
 Recent data indicate that microparticle associated tissue factor (MP-TF) activity is 
increased in patients with adenocarcinoma and that there is an association with the 
development of thrombosis(79). Our fourth aim is to assess the level of MP-TF activity in 
patients with MM prior to and during chemotherapy (chapter 5) and to determine whether 
this is related to the subsequent development of VTE.
 Recently, an increased thrombo-embolic incidence has also been reported in patients 
with other malignant and benign plasma cell disorders. Therefore we studied the levels of 
the above mentioned coagulation variables in patients with other plasma cell disorders such 
as Waldenstrom’s macroglobulinemia (WM), systemic Amyloidosis (AL) and monoclonal 
gammopathy of uncertain significance (MGUS) and compared these with our findings in 
MM patients (chapter 6). 
 Various prophylactic regimens, in order to prevent thrombo-embolic complications 
during the course of either first line of second line of therapy for MM, have been investiga-
ted and described in the literature. There is however, still debate regarding which antithrom-
botic prophylaxis regimen should be used. Therefore a study is initiated to investigate 
thrombo-prophylaxis with low molecular weight heparin (LMWH) in patients with MM, 
who are treated with a combination of chemotherapy and thalidomide. The aim of this 
study is to determine whether LMWH can reduce the incidence of VTE during anti-angio-
genic based chemotherapy (chapter 7). 
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 In chapter 8 we present a case history which illustrates how coagulation factor changes 
in multiple myeloma can alter the clinical phenotype of a patient with severe type 2A 
von Willebrand disease. In this case we studied the vWF/FVIII levels in a patient with 
von Willebrand disease who develops MM and experiences a temporary relief of bleeding 
symptoms during chemotherapy due to the increase of vWF levels (chapter 8).
 Finally a case is presented of a patient with a plasma cell disorder suffering from therapy 
resistant ulcerating vasculitis due to a MGUS related cryoglobulinemia (chapter 9). This 
patient developed a rare and severe complication as a result of frequent plasmapheresis 
with the plasma expander hydroxy-ethyl starch (HES). We extensively studied the accumu-
lation of HES a group of patients undergoing plasmapheresis in whom HES was used as 
plasma substitution.
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ABSTRACT
background
 A high incidence of thrombo-embolic complications has been reported in patients with 
Multiple Myeloma, especially when these patients receive multi-agent chemotherapy in 
combination with anti-angiogenic drugs. The mechanism is still poorly understood and 
studies regarding protrombotic risk factors are still limited. Therefore we studied various 
prothrombotic risk factors in large group of consecutive patients with newly diagnosed 
Multiple Myeloma. Patients were classified according to the recently introduced 
International Staging System.
patients and results
 A total of 135 MM patients and 124 healthy controls were included in this study. 
Increased factor VIII:C (FVIII:C 2.11 ± 1.15 U/ml) and von Willebrand factor antigen (vWF:Ag 
1.92 ± 1.13 U/ml) and ristocetin cofactor activity (vWF:RCo 1.78 ±1.08 U/ml) levels were 
observed compared to control subjects (p<0.001). The increase of FVIII and vWF levels were 
strongly related to the disease stage, with the highest levels in stage III. Protein S levels were 
significantly reduced in the most severe disease stage III compared to stage I.
conclusion
 Our study indicates that various prothrombotic abnormalities occur in patients with 
multiple myeloma, which may contribute to the increased the risk of venous thrombo-
embolism observed in these patients. 
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INTRODUCTION
 Patients with Multiple Myeloma (MM) are at a high risk for venous thromboembolism 
(VTE) with an incidence up to 30 percent, especially when receiving multi-agent chemotherapy 
and anti-angiogenic drugs (1-4). Several potential mechanisms have been suggested in the 
literature, such as increased viscosity as a result of high levels of circulation immunoglobulins, 
autoantibodies against natural anti-coagulants and increased cytokine levels(5). The first 
report on altered coagulation factors dates back to 1976 and concerned an observed 
increase in FVIII levels(6). However, only a few small-size studies on coagulation abnormalities 
in MM have been performed so far and these factors have yet not been studied in detail in 
a large group of untreated MM patients. Furthermore, it has not yet been elucidated what 
their contribution is to the development of VTE in patients suffering from MM. Recently, 
high levels of FVIII and vWF have been reported by Minnema et al. in patients with MM, 
which may contribute to the increased risk of thrombosis(7). Also, it has been postulated 
that acquired resistance to protein C, which was observed in up to 23 percent of patients 
with MM, may be associated with the increased VTE risk(8). Despite these reports, still only 
limited information is available on other prothrombotic coagulation abnormalities in 
MM patients. In order to further elucidate the underlying mechanisms for VTE in 
MM patients, we performed this prospective study to evaluate prothrombotic 
coagulation abnormalities in a large group of patients with newly diagnosed MM and whether 
this was related to disease status and the development of VTE.
MATERIALS AND METHODS
patients
 Consecutive patients with newly diagnosed MM according to the Mayo Clinic criteria(9) 
who were admitted to the department of Haematology of the Erasmus MC, an academic 
tertiary referral hospital, were included in the study. Patients who were eligible for intensi-
fied chemotherapy followed by high dose melphalan and autologous stem cell support. 
Their stage of disease was determined according to the recently introduced International 
Staging System (ISS)(10). Thromboprophylaxis consisting of low dose molecular weight 
heparin was given to the patients who received thalidomide based regimen. We also 
included a control group of 124 healthy controls, who were partners or friends of patients 
visiting the outpatient department of Haematology of our hospital. The Medical Ethical 
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Committee of the Erasmus MC approved the study and written informed consent was 
obtained from the patients before performing coagulation studies.
coagulation variables
 Venous blood was collected using a vacutainer system in citrate (0.105 M, Beckton-
Dickinson, Plymouth, UK) and centrifuged at 4°C at 2.000 g for 10 minutes. The collected 
plasma was additionally centrifuged for 10 minutes at 20.000 g and stored in small aliquots 
at –70°C until use. Genomic DNA was isolated from the white cell fraction of citrated 
blood, using a standard salting out procedure. FVIII:C was measured by a one stage clotting 
assay using Platelin (Organon Teknika,Durham, USA) and factor VIII deficient plasma 
(Biopool, Ventura, USA). VWF:Antigen (vWF:Ag) was measured by an in-house sandwich 
enzyme linked immunosorbent assay (ELISA) using rabbit anti-human vWF and horseradish 
peroxidase conjugated anti-human vWF (DakoCytomation, Glostrop, Denmark). vWF 
collagen binding activity (vWF:CB) was measured by an in-house EIA using type I collagen 
(Sigma, StLouis, USA) and horseradish peroxidase conjugated anti-human vWF. vWF 
Ristocetin Cofactor activity (vWF:RCo) was measured by an aggregometric method using 
formaline-fixed platelets and ristocetin (Diagnostiga Stago, Asnieres, France). All assays 
were calibrated with pooled normal plasma (factor assay control plasma, George King 
Bio-Medical, Kansas, USA). Fibrinogen was measured as described by von Clauss(11). 
Screening for lupus anticoagulant (LAC) was performed essentially as recommended by the 
Subcommittee on Lupus Anticoagulant / Antiphospholipid antibodies(12), and included 
screening assays (aPTT, PT and dilute prothrombin time) as well as confirmatory procedures 
to demonstrate the phospholipid dependence. The presence of lupus anticoagulant was 
tested by an aPTT based assay and a diluted (1:10 and 1:100) PT assay. If the initial test was 
abnormal, both of them were performed in a 1:1 mixture of patient and normal plasma. The 
aPTT-based lupus anticoagulant assay was performed with Platelin®LS (Organon Teknika, 
Oss, the Netherlands) and considered positive when longer than 34 seconds after 1:1 mixture 
with normal plasma. The diluted PT-assay was performed with diluted Recombiplastin® 
(Instrumentation Laboratory, IJsselstein, the Netherlands). The test was considered positive 
if the ratio in a 1:1 mixture with normal plasma was above 1.20. Anticardiolipin antibodies 
(ACA) were tested by enzyme-linked immunosorbent sandwich assay (ELISA), using cardiolipin 
(Sigma, Zwijndrecht, the Netherlands) and horseradish peroxidase conjugated-rabbit 
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anti-human IgG and IgM (Dakopatts). Anticardiolipin titers were calculated and considered 
positive if titers were above 32 U for IgG or above 12 U for IgM. Patients were considered 
antiphospholipid antibodies (APA) positive if one or both tests for APA were positive, i.e. if 
LAC was present and/or ACA-IgG or ACA-IgM were positive. The within assay variation coef-
ficient for the ACA assay was 10% for IgG and 11% for IgM. 
 Antithrombin activity levels were determined using a chromogenic substrate. For the 
measurement of protein S we used an assay (Staclot® Protein S, Diagnostica Stago) which 
is known not to interfere with FVIII when levels are lower than 250%(13). The prothrombin 
G20210A gene variant and the factor V Leiden mutation were identified simultaneously, 
using a multiplex PCR method previously described(14). Activated protein C (APC) resistance 
was determined on citrated plasma using an aPTT-based Food and Drug Administration-
approved resistance assay in the presence of excess factor V-deficient plasma (Coatest APC 
Resistance, Chromogenix Nodia/Schmidt). The ratios between the aPTT with or without the 
presence of activated protein C were calculated and the patient was considered positive if 
the ratio was less than 0.8.
statistical analysis
 Statistical analysis consisted of basic descriptive statistics and the results are presented 
as median ± standard. Levels of prothrombotic variables in the different ISS groups were 
compared using ANOVA, which takes multiple testing into account (Bonferoni correction 
with mean correlation=0.40). A p-value below 0.013 was considered significant.
RESULTS
patients
 One hundred and thirty-five consecutive patients with untreated MM admitted to the 
Department of Hematology of the Erasmus Medical Center, and academic tertiary referral 
hospital, who were eligible for intensified chemotherapy followed by high dose melphalan 
and autologous stem cell support were included in this study, as were 124 sex- and 
age-matched, healthy controls. The characteristics are summarised in Table 1. The median 
age of the patients was around 60 years and similar to the control group. Most of the 
patients were male (58%). The majority of the MM patients had ISS stage I or II (31% and 
56% respectively).
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prothrombotic risk factors in mm
 The results of the coagulation variables are presented in Table 2. The prevalence of factor 
V Leiden mutation and G20210A Prothrombin gene variant was similar in the MM patients 
and control group (Table 2). At baseline the incidence of lupus anti-coagulant (LAC) was 4% 
and for anti-cardiolipin antibodies (ACA) 6% in the MM patients. Anti-phospholipid 
antibodies (APA) were re tested after 3 months and had disappeared in all cases. 
 Von Willebrand Factor antigen levels were significantly increased in patients with MM 
(1.92 ± 1.13 U/ml) compared to the controls (1.17 ± 0.50 U/ml, p<0.0001). A similar 
increase in vWF:RCo and vWF:CB activity was also observed (Table 2). Furthermore, FVIII:C 
levels were significantly higher in MM patients compared to healthy controls (2.11 ±1.15 
versus 1.13 ±0.46 U/ml, P<0.001). In contrast, protein S activity levels in MM patients were 
in the lower normal range (0.72 ±0.25 U/ml). When staged according to the ISS criteria a 
significant difference in vWF antigen and activity levels in the various ISS stages was 
observed, with the highest levels in stage III (Table 2). This was also observed for Factor VIII:C 
levels. In addition, significantly lower protein S levels were seen in stage III disease compared 
to stage I. Other prothrombotic coagulation factors, including antithrombin, fibrinogen 
levels and D-dimer levels, were similar in patients and control subjects, and did not differ 
significantly between the ISS stages. 
 Thrombo-embolic complications were observed in 14 patients (10%) and occurred 
TABLE 1. PATIENTS CHARACTERISTICS
control multiple myeloma untreated
N 124 135
Age 57 (11.6) 58 (8.4)
Male gender (%) 53% 58%
B2M (mg/l) * 2.88 (5.42)
Platelets(x109/l) * 245 (79)
Albumin (g/l) * 37 (6.8)
Calcium (mmol/l) * 2.35 (0.24)
Hb (mmol/l) * 6.8 (1.2)
ISS stage I * 42 (31%)
ISS stage II * 75 (56%)
ISS stage III * 18 (13%)
# median (±SD of the mean). * not available
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most frequently during the induction chemotherapy (Table 3). There was no correlation 
between the ISS disease stage and the development of a VTE.
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DISCUSSION
 In our study of coagulation abnormalities in newly diagnosed untreated MM, FVIII and 
vWF antigen levels and activity were significantly higher in MM patients than in the 
controls. Furthermore, there was a significant correlation between prognostic disease stage 
according to ISS criteria and levels of FVIII and vWF, which were higher in stage III. The cor-
relation with disease stage according to the Durie and Salmon classification system was 
however, less clear. The pathogenetic mechanism of these increased levels is yet unclear, but 
may be related to the neovascularisation in the bone marrow stroma, which is accompanied 
by increased vasculature(15). Because vWF is synthesised mainly in endothelial cells, these 
bone marrow changes may eventually lead to increased vWF levels in plasma. vWF is a 
carrier protein for FVIII and FVIII levels will therefore also increase in MM. Another mecha-
nism for increased vWF levels may be the elevated interleukin-6 (IL-6) levels in serum of 
patients with MM. In the pathogenesis of Multiple Myeloma, IL-6 has been shown to play a 
pivotal role(16) and serum IL-6 levels are elevated in case of active disease(17). IL-6 plays a 
stimulatory role in the coagulation mechanism(18), because amongst others IL-6 promotes 
TABLE 3. THROMBO-EMBOLIC COMPLICATIONS DURING THERAPY
patient iss stage therapy at time of thrombosis thrombotic complication
Female (62yrs) I VAD DVT & PE
Male (49yrs) II VAD DVT
Female (45yrs) I HDM CVC thrombosis
Male (42yrs) I Radiotherapy* DVT
Female (65yrs) II VAD PE
Male (56 yrs) II VAD DVT
Female (58yrs) I TAD PE
Male (54yrs) II TAD DVT
Male (52yrs) I TAD PE
Female (48yrs) I TAD DVT
Female (46yrs) III CAD CVC thrombosis
Male (44yrs) I TAD PE
Male (58yrs) I PAD PE
Male (38yrs) II PAD DVT
A= adriamycin, B= Bortezomib, C= cyclophosphamide, D= Dexamethasone, 
T= thalidomide,V= Vincristine, HDM= high dose melfalan 
CVC= central venous catheter, *Radiotherapy performed prior to induction chemotherapy
35
C
hapter 2 - Prothrom
botic coagulation abnorm
alities in patients w
ith new
ly diagnosed M
ultiple M
yelom
a
the transcription of the Factor VIII gene(19). Recently it has been reported that IL-6, when 
in complex with the soluble IL-6 receptor, can induce hyperactive ultra large von Willebrand 
Factor (ULVWF)(20). IL-6 can also inhibit the cleavage of ULVWF resulting in an accumulation 
of this hyperactive ULVWF in plasma and on the surface of endothelial cells(18). This may 
also contribute to the increased vWF levels, and thereby of FVIII:C levels, in MM patients.
 An interesting observation was a significant decrease in protein S activity levels, especially 
in patients with ISS stage III MM compared to stage I. These reduced levels may be also 
related to the increased IL-6 levels in MM, as IL-6 has shown to reduce protein S levels in a 
canine model(21). The reduced protein S level may contribute to the increased risk for 
thrombo-embolic complications in the more severe stages of MM. Previously, a relationship 
between IL-6 and plasma fibrinogen levels has been reported(22). High levels of fibrinogen 
are associated with an increased incidence of thrombo-embolic complications(23) as well 
as the risk of recurrent thrombosis24. However, in our study we did not observe a significant 
increase of fibrinogen levels in patients with MM compared to an age and sex matched 
control group.
 In our patients with untreated MM the incidence of LAC and ACA were 4% and 6% 
respectively. This is higher than expected from the general population (0,9% and 1-5% 
respectively), and similar to the recently reported incidences in MM (24-26). This may also be 
related to the increased risk for thrombosis observed in patients with MM. These 
anti-phospholipid antibodies were retested after 3 months, as is recommended by the 
Sapporo criteria(12). In all cases these anti-phospholipid antibodies had disappeared after 
induction therapy. We found no relationship between positive APA tests and the presence of 
monoclonal IgG or IgA serum immunoglobulin, seen in the MM patients, which excludes the 
possibility that our findings are due to a cross reactivity of the monoclonal IgG and the APA tests.
 During normal haemostasis, APC limits clot formation by proteolytic inactivation of 
factors Va and VIIIa. Acquired APC resistance is associated with a sevenfold increased risk for 
deep vein thrombosis(27). In our study we found APC resistance in only 2% of the patients. 
This is in contrast to the previously reported incidence of 23%(8). We could therefore not 
confirm this observation.
  Thrombo-embolic complications were observed in 10% of the patients and occurred 
most frequently during the induction chemotherapy. Despite thromboprophylaxis 
consisting of low dose molecular weight heparin, which was given to the patients who 
36
received the thalidomide based regimen, VTE was observed with similar incidences in the 
various regimens. There was no correlation between the ISS disease stage and the 
development of a VTE. Furthermore, the coagulation variables prior to chemotherapy did 
not differ significantly between the patients who did and who did not develop a VTE. 
However, the number of patients with VTE in our study is low and this research question 
should be addressed in larger cohorts of multiple myeloma patients.
CONCLUSION
 Our study indicates that various prothrombotic abnormalities occur in patients with 
newly diagnosed untreated multiple myeloma, including an increase in vWF, Factor VIII, an 
increased incidence of anti-phospholipid antibodies and a slight decrease in protein S levels. 
The delicate balance between coagulation and fibrinolysis in multiple myeloma patients 
may be further disturbed by hypofibrinolysis, as has previously been reported(28), 
especially during chemotherapy(29). This results in a hypercoagulable state, which may 
promote the development of thrombo-embolic complications.
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ABSTRACT
background
 Venous thromboembolism (VTE) occurs frequently in multiple myeloma patients, espe-
cially during induction treatment with thalidomide in combination with anthracyclines 
and/or dexamethasone. Several coagulation abnormalities have been described in untrea-
ted myeloma patients, but these have not been prospectively evaluated during and after 
treatment.
patients and results
 We performed a prospective study in 138 multiple myeloma patients in whom coagu-
lation factor levels were evaluated longitudinally before, during induction and after intensi-
fication. Patients were randomized to induction treatment consisting of adriamycin and 
dexamethason, in combination with either vincristin (VAD), thalidomide (TAD), or bortezo-
mib (PAD) followed by high dose melphalan and autologous stem cell transplantion (ASCT).
 Factor VIII:C (FVIII:C) and von Willebrand factor (vWF) were significantly elevated be-
fore treatment (median FVIII:C 2.26 U/ml, vWF:Ag 1.95 U/ml). Irrespective of the type of 
induction regimen, these variables increased strongly during induction therapy (FVIII:C 2.55 
U/ml and vWF:Ag 2.96 U/ml). Fibrinogen also showed a significant increase after induction 
therapy (3.5 g/l pre-treatment and 4.0 g/l after treatment, respectively, p<0.001). This was 
significantly higher in TAD than VAD treated patients. Three to six months after ASCT levels 
of vWF and FVIII:C had decreased to values lower than observed before treatment (1.71 U/
ml and 1.67 U/ml respectively). There was no correlation between the increased levels at 
start and the response of multiple myeloma to treatment. High levels of vWF, fibrinogen 
and FVIII:C before start of treatment were significantly associated with mortality. Fourteen 
patients (10%) developed a venous thrombotic event (VTE). The coagulation factor abnor-
malities before and during treatment were not associated with the development of VTE. 
conclusion
 During induction treatment several changes in coagulation factor levels are observed, 
which may result in a prothrombotic state. Larger studies are required to establish whether 
the changes in these coagulation factors during induction treatment contribute to the in-
creased risk of venous thrombo-embolism in multiple myeloma patients. 
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INTRODUCTION
 Multiple Myeloma (MM) is associated with an increased risk for venous thromboembo-
lism (VTE). This risk is even higher when multi-agent chemotherapy and/or prednisone are 
combined with anti-angiogenic drugs, such as thalidomide(1-3). The combination of thali-
domide and doxorubicin is associated with the occurrence of venous thrombosis in 10-30% 
of the patients, whereas venous thrombosis occurs in only 1-5% of the patients receiving 
more conventional medication(4-7). Low molecular-weight heparin has been shown to re-
duce effectively the risk of VTE during thalidomide treatment(8, 9). Treatment with the re-
cently introduced proteasome inhibitor bortezomib has not been associated with an incre-
ased incidence of venous thrombosis(10). However, bortezomib has so far only been used 
as rescue or second line treatment, whereas an increased incidence of VTE is especially seen 
during induction treatment of newly diagnosed MM (11).
 Multiple alterations in the hemostatic system promoting coagulation have been found 
in untreated myeloma patients, including elevated levels of factor VIII:C (FVIII:C) and von 
Willebrand factor (vWF), activated protein C (APC) resistance, and a hypofibrinolytic state 
(3, 11-15). Elice et al. studied APC resistance before and after treatment. Nine percent of the 
patients had a transient APC resistance, which was associated with an increased risk of 
VTE(16).
 Because VTE occurs mainly during the induction treatment of multiple myeloma, it is of 
utmost interest to study the coagulation disorders during treatment. Therefore we evalua-
ted coagulation factor levels longitudinally before, during and after different intensive che-
motherapeutic regimens. The aim was to find coagulation factor abnormalities, which might 
correlate with an increased VTE risk and outcome of therapy. A second aim was to investi-
gate whether the various chemotherapeutic regimens are associated with different coagu-
lation profiles.
MATERIALS AND METHODS
patients
 Consecutive patients under the age of 65 years with newly diagnosed MM according to 
the Mayo clinic criteria who were admitted to the department of Hematology of the 
Erasmus MC Rotterdam or the University Medical Center Utrecht, both academic tertiary 
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referral hospitals in the Netherlands, were included in the study. Only patients who were 
eligible for intensive chemotherapy followed by high dose melphalan and autologous stem 
cell support were included. Informed consent was obtained from all patients. According to 
the Declaration of Helsinki, the protocol was approved by the Research Ethics Board of both 
participating hospitals. Patients were randomized to receive 3 courses of adriamycin, dexa-
methasone in combination with either thalidomide (TAD) or vincristine (VAD) (HOVON 
50-study)(17) or in combination with bortezomib (PAD, 1.3mg/m2, day 1,4,8, and 11) (HO-
VON 65-study, ongoing) as induction treatment in all patients followed by stem cell mobi-
lization with cyclophosphamin, adriamycin and dexamethasone (CAD) and intensive treat-
ment with high dose melphalan (HDM, 200mg/m2) and autologous stem cell 
transplantation as previously discribed(17). The starting dose of thalidomide was 100mg 
and could be escalated to 200mg. Thalidomide was stopped before stem cell mobilisation 
and re-administered after the autologous stem cell transplantation in a lower dose (50mg). 
Patients receiving thalidomide also received LMWH during the induction phase of treat-
ment. Patients receiving VAD in the HOVON 50 trial also received IFN (3x 106 IU, 3 times 
weekly) as maintenance therapy after stem cell transplantation. Patients treated with bor-
tezomib received bortezomib (1.3mg/m2, twice monthly) as consolidation.
methods
 Blood samples were collected at time of diagnosis before start of treatment (time point 
1), directly after therapy with VAD, TAD or PAD (time point 2), and 3 to 6 months after high-
dose melphalan (HDM) treatment (time point 3). Venous blood was collected using a vacu-
tainer system in citrate (0.105 M, Beckton-Dickinson, Plymouth, UK) and centrifuged at 4° 
C at 2000 g for 10 minutes. The collected plasma was additionally centrifuged for 10 mi-
nutes at 2000 g and stored in small aliquots at –70°C until use. Genomic DNA was isolated 
from the white cell fraction of citrated blood, using a standard salting out procedure.
 FVIII:C was measured by a one stage clotting assay using Platelin (Organon Teknika,Durham, 
USA) and factor VIII deficient plasma (Biopool, Ventura, USA) or a commercial coagulation 
method (Boehringer Mannheim, Mannheim, Germany). vWF: Antigen (vWF:Ag) was measu-
red by using the LIA test (Boehringer Mannhein, Mannheim, Germany or an in-house sand-
wich enzyme linked immunosorbent assay (ELISA) using rabbit anti-human vWF and hor-
seradish peroxidase conjugated anti-human vWF (DakoCytomation, Glostrop, Denmark). 
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vWF collagen binding activity (vWF:CB) was measured by an in-house EIA using type I col-
lagen (Sigma, StLouis, USA) and horseradish peroxidase conjugated anti-human vWF. vWF 
Ristocetin Cofactor activity (vWF:RCo) was measured with an aggregometric method using 
formaline-fixed platelets and ristocetin (Diagnostiga Stago, Asnieres, France). All assays 
were calibrated with pooled normal plasma (factor assay control plasma, George King Bio-
Medical, Kansas, USA). Fibrinogen was measured as described by von Clauss(18). Screening 
for lupus anticoagulant (LAC) was performed essentially as recommended by the Subcom-
mittee on Lupus Anticoagulant / Antiphospholipid antibodies and was described earlier(19, 
20). Anticardiolipin antibodies (ACA) were tested by enzyme-linked immunosorbent sand-
wich assay (ELISA), using cardiolipin (Sigma, Zwijndrecht, the Netherlands) and horseradish 
peroxidase conjugated-rabbit anti-human IgG and IgM (Dakopatts). Anticardiolipin antibo-
dies (ACA) were tested by enzyme-linked immunosorbent sandwich assay (ELISA), using 
cardiolipin (Sigma, Zwijndrecht, the Netherlands) and horseradish peroxidase conjugated-
rabbit anti-human IgG and IgM (Dakopatts). Anticardiolipin titers were calculated and con-
sidered positive if titers were above 32 U for IgG or above 12 U for IgM. Patients were 
considered antiphospholipid antibodies (APA) positive if one or both tests for APA were 
positive, i.e. if LAC was present and/or ACA-IgG or ACA-IgM were positive. The within assay 
variation coefficient for the ACA assay was 10% for IgG and 11% for IgM. Antithrombin 
activity levels were determined using a chromogenic substrate. Protein S was measured 
using an assay (Staclot® Protein S, Diagnostica Stago) which is known not to interfere with 
FVIII:C, when FVIII:C levels are lower than 2.5 U/ml (21). The prothrombin G20210A gene 
variant and the factor V Leiden mutation were identified simultaneously, using a multiplex 
PCR method previously described(22). Activated protein C (APC) resistance was determined 
on citrated plasma using an aPTT-based Food and Drug Administration-approved resistance 
assay in the presence of excess factor V-deficient plasma (Coatest APC Resistance, Chromo-
genix Nodia/Schmidt). The ratios between the aPTT with or without the presence of activa-
ted protein C were calculated and the patient was considered positive if the ratio was less 
than 0.8. Laboratory reference values were obtained from 40 healthy volunteers. Response 
to therapy was evaluated according to the EBMT criteria(23).
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STATISTICAL ANALYSIS
 Basic descriptive statistics are presented as median and interquartile range for conti-
nuous variables and as count (percentages) for categorical variables. Differences between 
groups and effects over time in the total group were tested using analysis of variance 
(ANOVA) and significant differences were further analyzed using Scheffé multiple-compa-
rison post-hoc analysis. Effects over time between groups were compared using the linear 
mixed-effects model fit by REML(24), taking into account the course of the vWF and FVIII:C 
levels within the same patient. A two-sided value of P<0.05 was considered statistically 
significant. Statistical analysis was performed with SPSS for Windows, version 11.5 (SPSS 
Inc. Chicago, USA).
RESULTS
patient characteristics
 A total of 138 patients with multiple myeloma (MM) were included in this prospective 
study on coagulation variables, of whom 41 (30%) had stage I, 77 (56%) stage II and 20 
(14%) had stage III disease according to the ISS criteria(25). The mean age was 55.2 years 
(range 22-71) and 57 % were males. Seventy-six patients received VAD, 45 TAD and 17 PAD. 
Baseline patient characteristics were not significantly different between the three treat-
ment groups and are summarized in Table 1. 
TABLE 1. PATIENT CHARACTERISTICS
therapy
VAd tAd pAd
N 76 45 17
Age (yrs) 56 (7.2) 54 (8.4) 52 (8.1)
Male gender (%) 61% 56% 65%
B2M (mg/l) 4.5 (6.4) 4.9 (4.4) 4.1 (2.0)
Platelets (x109/l) 248 (71) 229 (92) 221 (92)
Albumine (g/l) 36 (6) 35 (8) 35 (7)
Calcium (mmol/l) 2.31 (0.17) 2.38 (0.33) 2.37 (0.31)
Hb (mmol Fe/l) 7.0 (1.1) 6.6 (1.4) 6.4 (1.3)
ISS (n) I 25 11 5
II 43 25 9
III 8 9 3
Numbers are median (IQR), ISS= international staging system, V= vincristine, 
 A= adriamycine, T= thalidomide, B= bortezomib
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 baseline coagulation variables 
 The baseline coagulation variables are summarized in Table 2. Screening for lupus anti-
coagulant, the factor V Leiden mutation and the G20210A gene variant revealed a similar 
incidence compared to the normal population. FVIII:C and vWF:Ag were strongly elevated 
(2.26 [1.61] (median[IQR]U/ml and 1.95 [1.49] U/ml respectively) and a strong correlation 
between the vWF and FVIII:C levels was observed (r= 0.88, P<0.0001). VWF:Ag levels were 
strongly correlated with vWF collagen binding (vWF:CB) and ristocetin-cofactor activity 
(vWF:RCo) (r= 0.86 and r= 0.89 respectively, both P<0.0001).
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baseline values and the relationship with outcome.
 Response to treatment was assessed after induction therapy and 3 to 6 months after 
autologous stem cell transplantation. At the end of treatment, most patients showed a re-
mission (85%) of which 14% complete and 86% partial. In the total patient group we stu-
died the association between coagulation abnormalities observed before start of treatment 
with outcome during and after treatment. We observed no association between pretreat-
ment levels of vWF, FVIII:C and fibrinogen and the response at the end of treatment. Two 
patients died during the induction phase while receiving VAD or TAD. Two other patients 
that had received TAD or PAD died during the intensification phase. All these four patients 
were in the ISS stage III. The cause of death in all four patients was sepsis during neutrope-
nia. The pretreatment levels of vWF:Ag, FVIII:C and fibrinogen in these patients were signi-
ficantly higher than in those who survived (vWF:Ag; 3.64 [1.02] vs 2.07 [1.02] p=0.007 
(median [IQR]), FVIII:C; 4.37 [1.42] vs 2.26 [1.00], p<0.001 (median [IQR]) and fibrinogen; 
3.4g/l ±1.73 vs 5.35±4.3, P<0.002 (median [IQR]), for survivors and non-survivors respecti-
vely. 
coagulation factor levels during treatment
 We compared levels of various coagulation factors during and after treatment in the 
total patient group. FVIII:C (p=0.003) and vWF:Ag (p=0.03) levels showed a parabolic 
course during the treatment phases with the maximal values after induction treatment in 
all three groups (VAD, TAD and PAD) (Table 2). This increase was significant for FVIII:C (from 
2.26 [1.61] U/ml to 2.55 [1.78] U/ml) and vWF:Ag (from 1.95 [1.49] U/ml to 2.96 [2.0] U/
ml) between time points 1 and 2. The decrease between time points 2 and 3 was also 
significant (Table 2). There was however, no difference between the type of induction regi-
men and the course of FVIII:C (Figure 1) nor vWF. Fibrinogen levels were also significantly 
increased (from 3.5 to 4.0g/l) during treatment and remained elevated at the end of treat-
ment (3.70, P<0.001). 
 In the linear mixed-effects analysis of the three time points, fibrinogen levels were sig-
nificantly different between the VAD and TAD group. The increase between time point 1 and 
2 was higher in TAD group(t=1; 3.2g/L [IQR 0.9] and t=2; 4.3g/L [IQR 1.7]) versus the VAD 
group (t=1; 3.7g/L [IQR 1.3] and t= 2; 4.2g/L [IQR 1.4])(Figure 2). The PAD group consisted 
of 17 patients and was to small for subgroup analysis. Although antithrombin, protein C or 
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protein S levels increased slightly during induction chemotherapy, these levels remained 
within the normal range. D-dimer levels were decreased significantly at the end of treat-
ment compared to base line. 
coagulation factor levels and Vte
 Of the 138 patients included in this study, 14 patients experienced a venous thrombotic 
event. In one patient VTE occurred during radiotherapy prior to the start of chemotherapy. 
Thirteen patients developed a VTE during chemotherapy. These VTE were observed during 
all three chemotherapeutic regimens (VAD 8%, TAD 13% and PAD 6%) and were mainly 
observed during the induction phase (VAD n=4, TAD n=5 and PAD n=1). Two patients expe-
rienced a VTE during the CAD chemotherapy and one during the HDM treatment. We found 
no relationship between coagulation factor abnormalities before treatment, or after induc-
tion therapy and the risk of VTE (data not shown). 
 
DISCUSSION
 In accordance with previous studies, we found several coagulation abnormalities in pa-
tients with multiple myeloma before start of treatment. This study shows that these coagu-
lation abnormalities worsen during induction treatment with combination chemotherapy. 
Figure 1. Levels of FVIII:C and fibrinogen at the three different time points during the VAD, TAD or PAD treatment. Shown 
are box and whisker plots in which the data in box represents the 25-75% range with the median shown as line. The mi-
nimum and maximum levels are given as high/low bars.
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In the VAD, TAD and PAD treated patients vWF and FVIII:C levels increased during chemo-
therapy, and decreased again after high dose melphalan treatment and ASCT. Most coagu-
lation abnormalities exhibit a similar course during all three different treatment modalities 
except for fibrinogen, which was significantly higher in the TAD than in the VAD treated 
patients. Mortality during the induction treatment was significantly associated with high 
levels of FVIII:C, vWF and fibrinogen. 
 vWF and FVIII:C levels were strongly elevated in the patients at the time of diagno-
sis(11, 26). No difference was seen between the patients treated with PAD compared to the 
patients treated with VAD or TAD. vWF antigen levels correlated strongly with vWF functi-
onal activity measured by both ristocetin cofactor activity and collagen binding activity, 
indicating that the vWF in multiple myeloma patients is functionally normal. However, no 
differences in vWF and FVIII:C levels between the various regimens were observed. These 
results implicate that although increased FVIII:C levels may contribute to the increased risk 
of VTE in myeloma patients, these levels are unrelated to the increased thrombosis risk that 
is reported with TAD as compared to VAD or PAD. The patients who were treated with TAD 
also received LMWH as thrombo-prophylaxis. Previous studies have shown that vWF re-
lease may be influenced by unfractionated heparin, and to a lesser extent by LMWH (27, 
28). This indicates that in the patients treated with TAD, the rise of vWF levels may be un-
derestimated, due to the concomittant use of LMWH. In a previous study however, we have 
shown that levels in thalidomide treated multiple myeloma patients not receiving LMWH 
were similar to those in patients treated with other chemotherapeutic regimens (11). Simi-
larly, we recently described an induction of hypofibrinolysis during treatment of multiple 
myeloma, which may contribute to the increased thrombotic risk, but also in this study, no 
differences between VAD and TAD treated patients were observed(12). Fibrinogen levels 
showed a significant higher increase after induction treatment compared to patients who 
received VAD or PAD. This might explain the higher risk of VTE in TAD treated patients, be-
cause high fibrinogen levels are related to an increased thrombotic risk(29). In our study 
LMWH was administered as thrombo-prophylaxis in the patients receiving TAD during the 
induction phase to reduce the incidence of VTE. Recent data however, also suggest a pos-
sible role for platelets in the pathogenesis of multiple myeloma associated VTE(30). Since 
the use of prophylactic fixed low-dose aspirin in patients treated with a thalidomide based 
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regimen has indeed been shown to reduce the VTE incidence(31). 
 Recently bortezomib was introduced as a new powerful treatment modality in multiple 
myeloma. It has been primarily used in relapsing of refractory multiple myeloma patients, 
and low incidences of VTE complications were reported(10). However no studies have been 
reported on VTE risk associated with bortezomib as induction treatment in untreated mul-
tiple myeloma patients. In our study we found similar coagulation disorders in patients 
treated with PAD compared with VAD. One patient treated with PAD developed a trombotic 
event during the induction treatment. 
 We found no relationship between coagulation parameters before and during treatment 
with the development of VTE. Fourteen patients (10% of our study population) developed 
a VTE, mostly during the induction treatment. Since all patients treated with TAD received 
thromboprophylaxis with LMWH, which has been shown to effectively reduce the incidence 
of thrombosis, it is difficult to assess the relationship between the coagulation abnormali-
ties and risk of VTE in our study(8). Interestingly, we observed that pretreatment levels of 
FVIII:C, vWF and fibrinogen were associated with the risk of mortality. Patients who died 
during treatment exhibited the highest levels of these coagulation factors. Because of the 
limited number of patients this relationship remains speculative and this finding should be 
confirmed in larger cohorts. Mortality may be related to the severity of the disease stage 
since all these patients that died had ISS stage III. Furthermore, as was previously shown, the 
vWF and FVIII:C levels were significantly associated with the ISS stage(26).
CONCLUSION
 In conclusion, this study shows that there is a significant increase in the levels of vWF, 
FVIII:C and fibrinogen during the induction therapy of multiple myeloma and that these 
levels, except for fibrinogen, decrease after the ASCT. Especially when treatment was com-
bined with thalidomide, fibrinogen levels exhibited the highest increase during induction 
treatment TAD compared to the VAD regimen. Larger studies are required to establish 
whether the rise in these prothrombotic coagulation factors contributes to the increased 
risk of venous thromboembolism in multiple myeloma during induction treatment. 
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ABSTRACT
background
 Patients with newly diagnosed untreated Multiple Myeloma (MM) are at high risk for 
thrombo-embolic complications, especially when they are treated with antracyclin based 
multi-agent chemotherapy in combination with anti-angiogenic drugs, i.e. thalidomide. The 
nature of this increased risk is yet poorly understood. In this study we analysed the longi-
tudinal change in fibrinolytic activity in these patients before and after receiving induction 
chemotherapy followed by high dose melphalan (HDM) and autologous stem cell trans-
plantation (ASCT). 
patients & results
 A total of 77 patients with newly diagnosed MM who were eligible for multi-agent 
chemotherapy followed by high dose melphalan with ASCT were analysed. The data were 
compared with a control group of 133 healthy volunteers. Patients received adriamycin and 
dexamethasone in combination with vincristin (VAD) or thalidomide (TAD) as induction 
therapy. Fibrinolytic activity was determined prior to and after induction therapy, as well 
as after high dose melphalan followed by ASCT. Clot lysis time was similar to the control 
subjects before treatment (controls vs patients: median 63 [44-91] minutes vs 65 [38-108] 
minutes). After induction chemotherapy the clot lysis time increased significantly in both 
the VAD and the TAD patients (68 [44-122] and 70 [49-107]. Following HDM and ASCT, clot 
lysis time returned to normal values. 
conclusion
 In this study we observed hypofibrinolysis after induction chemotherapy in patients 
with MM irrespective of the type of induction therapy. These changes in fibrinolysis may 
contribute to the increased thrombosis risk in patient with multiple myeloma. 
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INTRODUCTION
 Multiple myeloma is associated with an increased risk for venous thrombosis. The risk for 
venous thromboembolism is even higher in patients receiving multi-agent chemotherapy 
and/or prednisone combined with anti-angiogenic drugs. The combination of thalidomide 
and doxorubicin was reported to be associated with the occurrence of venous thrombosis in 
10-30% of the patients, whereas venous thrombosis occurs in 1-5% of the patients recei-
ving more conventional chemotherapeutic regimens(1, 2). Multiple hemostatic alterations 
promoting coagulation have been found in myeloma patients. These include high levels of 
factor VIII and von Willebrand factor, acquired activated protein C (APC) resistance, and the 
formation of procoagulant autoantibodies(3-5). Furthermore, it has been described that 
high levels of serum M-proteins and increased blood viscosity may interfere with fibrin 
polymerisation, resulting in a fibrin clot which is more resistant to fibrinolysis(6). Finally, 
high levels of plasminogen activator inhibitor type I (PAI-1) have been found in myeloma 
patients, which also results in inhibition of fibrinolysis(7).
 We recently reported that overall plasma hypofibrinolysis, as measured by a tissue fac-
tor and tissue plasminogen activator (tPA)-induced clot lysis assay, constitutes a risk fac-
tor for venous thrombosis in otherwise healthy individuals(8). In this study, we measured 
plasma fibrinolytic potential in myeloma patients during the course of therapy including 
either Vincristine, Adriamycin, and Dexamethasone (VAD), or Thalidomide, Adriamycin, and 
Dexamethasone (TAD) to investigate whether chemotherapeutic treatment, especially in 
combination with thalidomide is associated with plasma hypofibrinolysis, and may there-
fore be an explanation for the increased incidence of venous thrombosis.
MATERIALS AND METHODS
 We studied newly diagnosed multiple myeloma patients who were included in the HO-
VON 50 study, a prospective randomised phase III study on the effect of thalidomide com-
bined with adriamycin, dexamethasone and high dose melphalan. The protocol has been 
described previously(9). From a subset of patients plasma was available. Blood samples 
from 77 patients taken at time of diagnosis, between the second and third course of induc-
tion therapy with VAD (45 patients) or TAD (32 patients), and from 35 patients after stem 
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cell transplantation (SCT) in the TAD arm and 47 after SCT in the VAD arm were studied. 
Clot lysis time was measured as described previously(8). As it is known that clot lysis time 
strongly increases with age, we used data obtained from 133 healthy controls above 55 
years of age, which were recruited as part of the Leiden Thrombophilia Study (LETS). These 
data were published previously(8). The average age of our patient group was 57, while the 
age of the control group averaged 62. Statistical analysis was performed using the GraphPad 
InStat (GraphPad, San Diego, CA) software package. As there was a significant difference 
in standard deviations between the groups, we analysed data using the non-parametric 
Kruskal Wallis one-way analysis of variance (ANOVA) test. P values <0.05 were considered 
statistically significant. 
RESULTS
 Figure 1 shows clot lysis times of plasma samples obtained from myeloma patients at 
time of diagnosis, during VAD or TAD treatment, and after SCT, compared to clot lysis times 
from age-matched healthy controls. There was no significant difference in clot lysis time 
between the normal control group and the patients tested at time of diagnosis (controls 
median [range]: 63 [44-91] min vs patients 65 [38-108] min). However, there was a signifi-
cant increase of clot lysis time during both VAD (median [range]: 68 [44-122] min) and TAD 
(median [range]: 70 [49-107] min) as compared to clot lysis times of the control subjects 
indicating the development of hypofibrinolysis during chemotherapy (p<0.05, Kruskal Wal-
lis ANOVA with Dunn’s post test). After SCT, the clot lysis times were again not different 
from the control group in both the VAD (median [range]: 67 [43-113] min) and TAD (median 
[range]: 65 [47-105] min) arm.
 
Figure 1. Box and whisker plot showing clot lysis times of 
plasma samples obtained from healthy controls compared to 
myeloma patients at time of diagnosis, during VAD or TAD 
induction therapy, and after SCT while receiving thalidomide 
(TAD) or interferon-alpha (VAD) maintenance therapy. The 
data in box represents the interquartile range with the medi-
an shown as line. The total range of data is demonstrated by 
the high/low bars. Groups significantly different to the con-
trol group are marked with * where P < 0.05. For easy com-
parison, the diagnosis group is shown twice in the Figure.C
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DISCUSSION
 In this study we found no evidence of hypofibrinolysis in patients with multiple myelo-
ma at the time of diagnosis. A hypofibrinolytic state did develop during both TAD and VAD 
therapy, and after SCT the hypofibrinolytic state was again resolved. The specific induction 
of hypofibrinolysis during chemotherapy might indicate that the increased thrombotic risk 
associated with chemotherapy might be explained in part by defective clot lysis. However, 
no increased hypofibrinolysis associated with thalidomide treatment was observed. 
 In this study we used a plasma-based clot lysis assay, which was previously demonstra-
ted to be of clinical relevance, since hypofibrinolysis as detected with this assay was found 
to be a clear, and independent risk factor for the development of a first venous thrombosis 
in otherwise healthy individuals(8). As such, our overall assay is expected to yield more 
relevant information compared to the measurement of individual fibrinolytic factors. For 
example, the association of elevated levels of PAI-1, and decreased tPA levels with venous 
thrombosis has never been convincingly shown(10, 11). Also, other global tests of fibrino-
lysis such as the euglobulin clot lysis time and the dilute whole blood clot lysis time did 
not show a convincing association with the occurrence of venous thrombosis(12). Although 
the exact determinants of our clot lysis assay are still incompletely known, the available 
data suggest that the outcome of our test indeed reflects an overall plasma fibrinolytic 
potential(8, 13). An earlier study did show a hyperfibrinolytic state in multiple myeloma in 
a mixed population of which approximately half was sampled at the time of diagnosis(7), 
but this clot lysis assay employed citrated plasma, with an exogenously added fibrin clot, 
thereby obscuring the effects of thrombin generation and endogenous fibrin formation on 
the fibrinolytic potential. Furthermore, one study employing purified myeloma antibodies 
observed these antibodies to inhibit fibrinolysis in normal plasma(6). However, in our study, 
no correlation between serum M protein levels and clot lysis time could be demonstrated 
(data not shown). 
 The occurrence of hypofibrinolysis during chemotherapy is likely to contribute to the 
increased thrombotic risk in myeloma patients during this stage of treatment. However, 
we did not find a difference in the extent of hypofibrinolysis between patients receiving 
thalidomide and vincristine, indicating that the further increased thrombotic risk caused by 
administration of thalidomide is caused by alterations in a different part of the hemostatic 
system. Patients receiving thalidomide were also receiving low molecular weight heparin as 
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thromboprophylaxis, which could potentially have obscured clot lysis results(14). However, 
at the time of sampling, none of the patients had detectable plasma levels of low molecular 
weight heparin (as measured by an anti Xa assay, data not shown). 
CONCLUSION
 In conclusion, in this study we found an induction of hypofibrinolysis in patients with 
multiple myeloma during VAD and TAD treatment. These results may explain the elevated 
thrombotic risk in patients receiving induction chemotherapy with VAD or TAD. However, 
it does not explain the extra increased risk of VTE during thalidomide treatment, as hypofi-
brinolysis was observed both during VAD and TAD treatment. Presumably other hemostatic 
alterations are responsible for the thrombotic risk in myeloma patients during thalidomide 
therapy. 
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ABSTRACT
background
 An increased risk for venous thrombo-embolic (VTE) complications in patients with 
Multiple Myeloma (MM) has been reported, especially when these patients are treated with 
combination treatment including high dose dexamethason and doxorubicin. The addition 
of thalidomide can increase this risk up to 30%. Preventing these VTE complications and 
the choice of thromboprophylaxis remains a major issue. In this study we investigated the 
effectivenes of low molecular weight heparin (Nadroparin) in newly diagnosed MM patients 
who received multi-agent chemotherapy in combination with thalidomide.
patients and results
 A total of 412 patients with newly diagnosed MM were included in this study. The 
patients were randomised to receive either the combination of vincristin, doxorubicin and 
dexamethasone (group A: VAD) without thrombo-prophylaxis or thalidomide, doxorubicin 
and dexamethasone (group B: TAD) in combination with LMWH nadroparine 2850 IE anti-
Xa or 5700 IE anti Xa in case of weight above 90kg. Thirty cases of VTE were observed (7%; 
in group A 5% and group B 9%) and occurred especially during induction chemotherapy. 
Two patients in group B did not receive thromboprophylaxis at the time the VTE ocurred. 
No side effects were observed. 
conclusion
 In conclusion, standard LMWH (Nadroparin) prophylaxis during chemotherapy is safe 
and effective in reducing the incidence of thalidomide-associated VTE in newly diagnosed 
MM patients.
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INTRODUCTION
 In multiple myeloma (MM) patients, treatment with thalidomide has proven its efficacy 
as monotherapy, but also combined with dexamethasone and chemotherapy. However, 
in combination with these drugs thalidomide may increase the incidence of deep venous 
thrombosis and pulmonary embolism up to 30%(1). The pathogenesis of these thrombotic 
events is poorly understood and it is also not known how to prevent thalidomide-associ-
ated venous thromboembolism (VTE)(2). In patients who were treated in the prospective, 
multicenter phase III HOVON-50/GMMH-HD3 study, we evaluated the incidence of VTE 
in newly diagnosed MM patients during induction therapy with thalidomide, doxorubicin 
and dexamethasone when using the low molecular-weight heparin (LMWH) nadroparin in 
prophylaxis dosage. 
PATIENTS AND METHODS
 Patients, age 18-65 years, with newly diagnosed MM, Salmon & Durie stage II or III, 
were eligible for inclusion. Informed consent was obtained from all patients. According to 
the Declaration of Helsinki, the protocol was approved by the Research Ethics Board of each 
participating hospital. Patients were randomly assigned to induction chemotherapy consis-
ting of three cycles of vincristine (0.4 mg, i.v. on days 1-4), doxorubicin (9 mg/m2, i.v. on 
days 1-4) and dexamethasone 40 mg orally (days 1-4, 9-12, 17-20), (VAD) arm A. Patients 
assigned to arm B received thalidomide instead of vincristine (TAD). Cycle 2 starts at day 
29, cycle 3 at day 57. Thalidomide was given as 200 mg orally, starting at day 1 of the first 
TAD cycle and was stopped 2 weeks before chemotherapy for stem cell mobilization was 
started. The thalidomide dose could be escalated to maximally 400 mg in case of good to-
lerability. Patients in arm B started with standard dosage thrombosis prophylaxis consisting 
of subcutaneously LMWH nadroparin 2850 IE anti-Xa or 5700 anti-Xa in case of weight 
above 90 kg. Prophylaxis was started at day 1 of the first TAD cycle until 1 week before start 
of chemotherapy for stem cell mobilization. Stem cells were mobilized after cyclophosp-
hamide 1000 mg/m2 i.v. day 1, doxorubicin 15 mg/m2, i.v. on days 1-4, dexamethasone 40 
mg orally on days 1-4 (CAD) and G-CSF 5 mg/kg twice daily until collection. After induction 
therapy all patients received one or two courses of high-dose melphalan (HDM) 200 mg/
m2 with autologous stem cell rescue. Patients randomized to arm A received maintenance 
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therapy with α-interferon (3 x 106 IU, thrice weekly) and patients randomized to arm B 
received thalidomide 50 mg/day without VTE prophylaxis. The incidence of VTE was a se-
condary end point of the study and had to be reported directly by fax to the datacenters as 
a serious adverse event. The reporting hospitals were then contacted for further details. As 
control a separate questionnaire was sent to all participating hospitals. All types of venous 
thrombosis and pulmonary embolism were included and diagnosis was made by Doppler 
ultrasonography or spiral pulmonary computer tomography. The time to occurrence of the 
first VTE, TVTE , was calculated from the date of randomization. Patients who died within 6 
months without VTE were censored at the date of death. TVTE was estimated with the ac-
tuarial method of Kaplan and Meier and 95% confidence intervals were calculated, Kaplan-
Meier curves of TVTE were generated to illustrate differences between the two treatment 
arms, and the log-rank test was used to compare the two curves. The reported P-values are 
two-sided, and a significance level of α=0.05 was used. 
RESULTS
 Inclusion started in November 2001 and as of May 1, 2003, 412 patients were included, 
201 patients in Arm A and 211 patients in Arm B. The data were analyzed as of January 16, 
2004. In all, 30 cases of VTE were reported in 412 evaluable patients (7%, 95% CI 5-10%) 
(Table 1). 
VTE: venous thrombo-embolism, DVT; deep venous thrombosis, PE ; pulmonary embolism
VAD; vincristine, doxorubicin, dexamethasone, TAD; thalidomide, doxorubicin, dexamethasone 
Randomization arm A B Total
Inclusion 201 211 412
VTE 11 (5%) 19 (9%) 30 (7%)
VTE during VAD/TAD 8 (4%) 17 (8%) 25 (6%)
VTE localization
 DVT leg 8 14 22
 DVT leg+ PE 0 1 1
 PE 1 3 4
 DVT arm 2 1 3
Median days after start treatment (range) 79 (26-164) 60 (11-182)
Male/Female 6/5 13/6 19/11
Age, median (range) 55 (46-62) 54 (41-64)
Table 1. VTE incidence during chemotherapy and patients characteristics
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 There were 22 lower extremity thrombosis (DVT leg), one DVT leg with pulmonary 
embolism (PE), four PE and three arm venous thrombosis (DVT arm). One arm venous 
thrombosis (arm A) was catheter related. In arm A, 201 patients were included of whom 11 
patients developed VTE (5%, 95% CI 3-10%) at a median of 79 days (range 26-164) after 
randomization. VTE occurred in 19 patients in arm B (9%, 95% CI 6-14%), median 60 days 
(range 11-182) after randomization (P=0.15) (Figure 1).
 
Figure 1. VAD; vincristine, doxorubicin, dexamethasone, AD+ Thal; thalidomide, doxorubicin, dexamethasone 
 Most cases of VTE occurred during induction chemotherapy, eight cases during VAD and 
17 cases during TAD (P=0.08). In arm A, two cases were reported after CAD and one after 
HDM. In arm B, one patient developed a VTE after CAD and one patient after HDM. Two 
patients in arm B did not receive prophylaxis at the time of VTE while treated with TAD, in 
one patient prophylaxis was stopped to perform a bone marrow biopsy 1 week before VTE 
and one patient did not receive prophylaxis for unknown reasons. No side effects, especially 
bleeding, of nadroparine prophylaxis were reported. 
DISCUSSION
 This prospective study shows that with prophylactic dosage of the LMWH nadroparin the 
incidence of VTE during combined treatment of thalidomide, dexamethasone and doxoru-
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bicin is about 10%. This incidence is comparable with the incidence of VTE during intensive 
chemotherapy in newly diagnosed MM patients without the use of thalidomide(3). In the 
standard VAD arm of this study the incidence of VTE with vigorous monitoring was 5%. For 
ethical reasons there was no randomization between patients receiving VTE prophylaxis, 
because previous publications demonstrated such a high incidence of VTE. Furthermore, in 
arm B vincristine was left out because of high risk of polyneuropathy when combined with 
thalidomide. Therefore, only a comparison can be made with historical controls. Zangari 
et al(1) were the first to report the high incidence of thalidomide-associated VTE of 28% in 
the Total Therapy II trial during induction therapy with polychemotherapy consisting of vin-
cristine, doxorubicin, dexamethasone, cyclophosphamide, etoposide and cisplatin. Osman 
et al(4) reported an incidence of 27% in newly diagnosed patients using induction therapy 
consisting of thalidomide, doxorubicin and dexamethasone in almost similar dosages as in 
this study. A more recent study combined thalidomide with vincristine, doxorubicin and 
dexamethasone and reported four thrombotic events in the first 12 patients(5), that is, an 
incidence of 33% without the use of VTE prophylaxis, although Zervas et al(6) reported an 
VTE incidence of 10% with the same regime. These high VTE-incidences are also found in 
thalidomide-based therapy regimes without anthracyclines and in patients with refractory 
or relapsed MM patients(7, 8). Others have tried fixed low-dose warfarin as VTE prophylaxis 
but reported conflicting results. Zamagni et al used 1.25 mg warfarin daily and demonstra-
ted a decrease in VTE incidence of 26% to 9% when treating de novo MM patients with 
dexamethasone and thalidomide(9). However, others could not demonstrate a beneficial 
effect when using 1 mg fixed-dose warfarin, but also reported comparable VTE incidences 
with their control arm when changing to LMWH prophylaxis(10). 
CONCLUSION
 In conclusion, standard LMWH (nadroparine) prophylaxis during chemotherapy is safe 
and effective in reducing the incidence of thalidomide-associated VTE in newly diagnosed 
MM patients.
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ABSTRACT
background
 An increased incidence of thromboembolic complications has been observed in Multiple 
 Myeloma (MM), especially when patients are treated with antracycline-based chemo-
therapy. In MM patients, plasma levels of several prothrombotic coagulation factors are 
increased and this may contribute to the prothrombotic state of these patients. Recent-
ly, an increased thrombosis risk has also been described for other plasma cell disorders 
(PCD), such as Monoclonal Gammopathy of Uncertain Significance (MGUS) and systemic 
AL amyloidosis. The aim of this study was to analyse prothrombotic coagulation disorders 
in patients with paraprotein producing B-cell disorders, such as MGUS, AL amyloidosis and 
Waldenström’s Macroglobulinemia (WM) and MM. 
patients and results
 A total of 198 patients with paraprotein producing B-cell disorders including MGUS, 
MM, AL amyloidosis and WM were included in this study. Different coagulation variables 
regarding the primary and secondary hemostasis were analysed as well as known prothrom-
botic gene mutations (factor V Leiden and G20210A variant) and screening for lupus anti-
coagulant / antiphospholipid antibodies.
 An increase in factor VIII (FVIII) and von Willebrand Factor (vWF) was observed in pa-
tients with MGUS and AL amyloidosis that was similar to increases seen in patients with 
untreated MM. The highest levels were observed in patients with AL amyloidosis.
conclusion
In conclusion, we observed several coagulation abnormalities in patients with different PCD. 
These prothrombotic changes in patients with MM, AL amyloidosis and Waldenström’s Ma-
croglobulinaemia may be causally related to the observed incidence of VTE in these forms 
of PCD
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INTRODUCTION
 Multiple Myeloma (MM) is associated with an increased risk of venous thrombo- em-
bolism (VTE), especially in patients receiving multi-agent chemotherapy including anthra-
cyclines in combination with anti-angiogenic drugs such as thalidomide(1, 2). Recently an 
increased incidence of VTE in other paraprotein producing B-cell disorders, such as Mono-
clonal Gammopathy of Uncertain Significance (MGUS) and systemic Amyloidosis (AL), has 
also been reported. VTE has been reported with an incidence of 6-7.5% in MGUS(3-5) and 
11% in AL(6). In patients with MM, increased levels of Factor VIII (FVIII) and von Willebrand 
Factor (vWF) have been observed and are suggested to play an important role in the hy-
percoagulable state of these patients. Also acquired activated protein C resistance (APC) 
occurs in patients with multiple myeloma, which is related to the occurrence of VTE(7). 
The mechanism of VTE is however not fully understood and data regarding prothrombotic 
coagulation abnormalities in plasma cell disorders (PCD) other than MM are still limited. 
Therefore we compared prothrombotic coagulation factors in patients with various para-
protein producing B-cell disorders, including MGUS, AL, Waldenström’s Macroglobulinemia 
(WM) and compared these with our observations in patients with newly diagnosed MM. 
MATERIALS AND METHODS
patients
 198 consecutive patients with paraprotein producing B-cell disorders who were admit-
ted to the department of Hematology of the Erasmus University Medical Center, an acade-
mic tertiary referral hospital, were included in the study. We also included a control group 
of 125 healthy individuals, who were partners or friends of patients visiting the outpatient 
department of Hematology of our hospital. The Medical Ethical Committee of the Erasmus 
MC approved the study and written informed consent was obtained before performing 
coagulation studies.
coagulation variables
 Venous blood was collected using a vacutainer system in citrate (0.105 M, Beckton-
Dickinson, Plymouth, UK) and centrifuged at 4° C at 2000 g for 10 minutes. Plasma samples 
were obtained at time of diagnosis while the patients were not reveiving chemotherapy. 
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The plasma was collected and centrifuged for an additional 10 minutes at 2000 g and 
stored in small aliquots at –70°C until use. Genomic DNA was isolated from the white cell 
fraction of citrated blood, using a standard salting out procedure. FVIII:C was measured 
by a one stage clotting assay using Platelin (Organon Teknika, Durham, USA) and factor 
VIII deficient plasma (Biopool, Ventura, USA). vWF:Antigen (vWF:Ag) was measured by an 
in-house sandwich enzyme linked immunosorbent assay (ELISA) using rabbit anti-human 
vWF and horseradish peroxidase conjugated anti-human vWF (DakoCytomation, Glostrop, 
Denmark). VWF collagen binding activity (vWF:CB) was measured by an in-house EIA using 
type I collagen (Sigma, StLouis, USA) and horseradish peroxidase conjugated anti-human 
vWF. VWF Ristocetin Cofactor activity (vWF:RCo was measured by an aggregometric me-
thod using formaline-fixed platelets and ristocetin (Diagnostiga Stago, Asnieres, France). 
All assays were calibrated with pooled normal plasma (factor assay control plasma, George 
King Bio-Medical, Kansas, USA). Fibrinogen was measured as described by von Clauss(8). 
Screening for lupus anticoagulant (LA) was performed essentially as recommended by 
the Subcommittee on Lupus Anticoagulant / Antiphospholipid antibodies(9), and included 
screening assays (aPTT, PT and dilute prothrombin time) as well as confirmatory procedures 
to demonstrate the phospholipid dependence. Anticardiolipin antibodies were tested by 
enzyme-linked immunosorbent sandwich assay (ELISA), using cardiolipin (Sigma, Zwijnd-
recht, the Netherlands) and horseradish peroxidase conjugated-rabbit anti-human IgG and 
IgM (Dakopatts). Patients were considered aPL positive if one or both tests for aPL were 
positive. The within assay variation coefficient for the aCL assay was 10% for IgG and 11% 
for IgM. 
 Antithrombin activity levels were determined using a chromogenic substrate. Protein 
S activity was determined using the Staclot® Protein S assay (Diagnostica Stago) which is 
not influenced by high FVIII(10). The prothrombin 20210GA gene variant and the factor V 
Leiden mutation were identified(11). Activated protein C (APC) resistance was determined 
on citrated plasma using an aPTT-based resistance assay in the presence of excess fac-
tor V-deficient plasma (Coatest APC Resistance, Chromogenix Nodia/Schmidt). The ratios 
between the aPTT with or without the presence of activated protein C were calculated 
and the patient was considered positive if the ratio was less than 0.8 D-dimer levels were 
measured using the Biopool AutoDimer assay and expressed mg/l. Reference values in our 
laboratory were obtained from 40 healthy volunteers.
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STATISTICAL ANALYSIS
 Statistical analysis consisted of basic descriptive statistics and the results are presen-
ted as median with interquartile range. Differences between groups were analysed using a 
Kruskal-Wallis test and for those variables where differences exist among the means, post 
hoc range tests (Tukey) were used to identify which means differ. The statistical analysis 
was performed with SPSS software, version 11. 
RESULTS
 A total of 198 patients with paraprotein producing B-cell disorders and 125 control 
subjects were included in this study. The patient characteristics are summarized in Table 1. 
The median age was around 60 years and did not vary significantly between the different 
patient groups. Baseline genetic and plasma risk factors for thrombosis in the different 
groups of patients with PCD are presented in Table 2. 
table 1. patients characteristics
* mean (SD), # not available. Other variables are median (interquartile range)
 Antigen and activity levels of von Willebrand Factor (vWF) were significantly increased 
in patients with plasma cell disorders compared to the healthy control group. Subgroup 
analysis revealed that vWF antigen and activity levels were similarly increased in the pa-
tients with MM, MGUS and AL amyloidosis, but not in patients with WM( Figure 1). FVIII 
levels were also significantly increased in the total group of patients with PCD compared 
to the control group. The highest FVIII levels were seen in patients with AL amyloidosis 
(Figure 1). Although protein S activity was within the lower range of normal in all forms of 
control mgus multiple myeloma Amyloidosis Waldenstrom’s
N 125 25 145 20 8
Age* 55 (11.6) 64 (11.5) 56 (8.1) 57 (9.6) 66 (12.3)
Male gender (%) 53 64 58 40 88
B2M # 1.68 (1.4) 3.08 (2.8) 2.00 (1.79 2.87 (1.3)
Platelets # 262 (108) 243 (102) 311 (224) 190 (95)
Albumine # 41 (4) 37 (9) 43 (13) 33 (5)
Calcium # 2.35 (.016) 2.34 (.024) 2.30 (0.36) 2.27 (0.22)
Hb # 8.6 (1.1) 6.8 (1.7) 8.8 (2.5) 6.5 (1.8)
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PCD, there was no significant difference between the various groups. Fibrinogen levels were 
significantly higher in the patients with Amyloidosis compared to the other PCD. The fre-
quencies of the Factor V Leiden mutation and the prothrombin 20210A gene variants were 
similar in patients with PCD and control subjects. Acquired APC resistance was observed in 
only a few patients. The incidence of lupus anticoagulant varied between 5 and 33 percent 
(MGUS and AL Amyloidosis respectively). None of the tested patients had anti-cardiolipin 
IgM antibodies whereas IgG was observed in only a few of the patients suffering MM and 
WM (Table 2).
Figure 1. vWF and Factor VIII levels and activity in various plasma cell disorders.
DISCUSSION
 Recently, we reported increased levels of FVIII and vWF in patients with untreated 
MM and that there was a significant difference between the various ISS stages(12). In the 
present study we also observed an increase in the level and activity of FVIII and vWF in 
patients with other PCD.
 Previous studies have indicated that angiogenesis is increased in MM and that the extent 
of angiogenesis has prognostic value in the disease(13). Since vWF is mainly synthesized 
and stored in endothelial cells, an increase in bone marrow neovascularisation is suggested 
to contribute to this increase in vWF activity. It has been shown that bone marrow angioge-
nesis progressively increases along the spectrum of PCD from the more benign MGUS stage 
to advanced myeloma(14). This would suggest an increase of vWF along the same scale. 
We did observe that vWF is also increased in other PCD and that there was no difference 
between the various forms of PCD. The highest levels were observed in patients with AL 
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amyloidosis. However, it has been reported that in these patients, bone marrow angiogene-
sis seems to be normal(14). Furthermore, in patients with WM only a minority exhibit incre-
ased angiogenesis(15). This suggests that other mechanisms, such as inflammation, might 
also be involved in the pathogenesis of increased levels of vWF. IL-6 plays a stimulatory role 
in the coagulation mechanism(16), because IL-6 promotes the transcription of the Factor 
VIII gene(17). Recently it has been reported that IL-6, when in complex with the soluble IL-6 
receptor, can also induce hyperactive ultra large von Willebrand Factor(18). Furthermore, 
Zezos et al observed a correlation between vWF activity and acute phase reactants (APRs), 
such as the erythrocyte sedimentation rate and C-reactive protein in patients with inflam-
matory diseases(19). Elevated vWF activity might therefore also represent an endothelial 
component of the acute-phase response(20, 21). In our study we mainly focussed on the 
coagulation system and did not measure markers of APRs, besides fibrinogen. 
 During normal hemostasis, activated protein C (APC) limits clot formation by proteo-
lytic inactivation of factors Va and VIIIa. APC resistance may be acquired in patients with 
malignancy(22). In our patients we observed acquired APC resistance in only a few patients 
with untreated MM and in other PCD. In previous studies, acquired APC resistance was 
observed in 6 to 23 percent of patients with MM (7, 23, 24). Furthermore, acquired APC 
resistance has recently been shown to be associated with a increased risk for deep vein 
thrombosis in patients with MM and it tends to disappear after treatment(24). We have no 
explanation for the difference between our observation and that reported in the literature, 
but it may be caused by the different assay used in our study.
 Patients with AL amyloidosis are known to have various coagulation abnormalities. 
Some rare encountered coagulation abnormalities in AL amyloidosis are hyperfibrinolysis 
or factor X deficiency which can result in a severe bleeding tendency(25, 26). This is only 
observed in a minority of the AL amyloidosis patients and is associated with a specific 
coagulation factor disorder, for instance due to absorption of factor X by amyloid fibrils or 
increase of urokinase type plasminogen activator levels. On the other hand, an increased in-
cidence of VTE (11%) in amyloidosis has recently been reported(6). Our data from a group 
of 20 patients revealed that FVIII and vWF levels were both strongly increased which may 
result in a hypercoagulable state. 
 Analysis on antiphospholipid antibodies revealed an incidence of 12% lupus anticoagu-
lant in the untreated MM patients, which is a higher incidence than recently reported by 
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Hugo et al(23). Anticardiolipin IgG antibodies were detected in a small number of patients 
with newly diagnosed MM (6%) and MW (13%) whereas no ACL IgM antibodies were ob-
served. Recently similar low incidences have been reported by Zangari et al(7). 
 It would be of interest to analyse the association between the thrombophilia markers 
and risk of thrombosis in our group of patients. However, only three patients (2 MGUS and 
1 AL amyloidosis) and fourteen patients (10%) with newly diagnosed MM who received 
anthracyclin based multi-agent chemotherapy developed a thrombo-embolic complication. 
The venous thrombotic events included central venous catheter associated thrombosis of 
the arm in 14%, deep venous thrombosis of the lower extremity in 50% , and pulmonary 
embolism in 37% of the events. The number of patients with VTE in our study is limited and 
larger studies are required to study the relationship between coagulation abnormalities in 
PCD and the development of VTE.
CONCLUSION
 In conclusion, we observed several coagulation abnormalities in patients with different 
PCD. No major differences were observed for the different subgroups. The thrombophilic 
state in patients with MM, AL amyloidosis and Waldenström’s Macroglobulinaemia may be 
causally related to the observed increased incidence of VTE in these forms of PCD. 
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INTRODUCTION
 Multiple Myeloma can be associated with various hemostatic abnormalities which 
predispose the patient to either venous thromboembolism or hemorrhage. Recently Min-
nema et al reported increased levels of von Willebrand factor and factor VIII in patients 
with multiple myeloma which may result in a prothrombotic state(1). In this chapter we 
report a patient with type 2A von Willebrand disease who experienced relief of hemorrhagic 
symptoms due to the development of a multiple myeloma.
CASE REPORT
 Recently a 55-year old male patient was referred to our hospital for treatment of mul-
tiple myeloma. In his youth he presented with a bleeding diathesis, due to type 2A Von 
Willebrand Disease (vWD). Laboratory investigation in the past showed FVIII:C of 0.23 U/
ml (normal 0.6-1.4), Von Willebrand Factor: Antigen (vWF:Ag) 0.12 U/ml (normal 0.6-1.4 U/
ml), vWF:Ristocetin cofactor activity (vWF:RCo) <0.10 U/ml (normal 0.6-1.4), vWF:Collagen 
binding activity (vWF:CB) <0.05 U/ml (normal 0.6-1.4). Multimer analysis performed by 
SDS gel electrophoresis, showed absence of high molecular weight vWF multimers. He had 
recurrent episodes of epistaxis for which he was treated regularly with tranexamic acid. In 
addition he underwent several surgical interventions after infusion of FVIII/vWF concen-
trate (Haemate P, ZLB Behring, Zaventem, Belgium), with normal recovery of FVIII and vWF. 
In his family several other members were diagnosed with vWD also, including his father, 
brother, son and daughter, and two grand-children, indicative of an autosomal dominant 
trait. This confirms the hereditary nature of vWD and excludes an acquired von Willebrand 
syndrome.
 In 2003 he noticed that the frequency of epistaxis diminished while symptoms of fati-
gue and fever occurred. Laboratory investigations revealed an increased ESR (67mm/hr) and 
a serum monoclonal IgG-kappa (65 g/l). In the bone marrow aspirate infiltration by mono-
clonal plasma cells (>60%) confirmed the diagnosis multiple myeloma. Laboratory investi-
gations at that moment revealed increased plasma levels of FVIII:C of 1.29 U/ml, vWF:Ag of 
0.9 U/ml, and vWF:CB of 0.56 U/ml. vWF:RCo level remained low (0.18 U/ml). The patient 
received three courses of Thalidomide, Adriamycin and Dexamethasone according to the 
prospective phase III HOVON 50/GMMG-HD3 study. During treatment IgG-kappa levels 
100
decreased to 9 g/l, resulting in a good partial response. This co-incided with a decrease of 
FVIII:C and vWF antigen and activity to pre-existing levels (Figure 1). In addition he again 
encountered several episodes of epistaxis.
Panel A Panel B
Figure 1: Plasma levels of vWF, Factor VIII and IgG during the course of treatment (panel A) and SDS agarose gel electrop-
horesis of vWF multimers pattern (panel B)
 
DISCUSSION
 Multiple myeloma has primarily been associated with a bleeding tendency due to ac-
quired von Willebrand syndrome, factor X deficiency or thrombocytopenia(2, 3). Recently 
however, an increased risk of venous thromboembolism (VTE) has been reported in patients 
with multiple myeloma in particular during treatment with doxorubicin and thalidomide(4, 
5). The mechanism of the increased thrombotic tendency has not yet been fully elucidated. 
In multiple myeloma patients high levels of FVIII:C have been reported and a causal relation 
has been suggested(1). It is already known from population based studies that high FVIII:C 
levels may be associated with an increased risk of VTE(6). The increase in FVIII:C in multiple 
myeloma is probably caused by an increased half-life due to high levels of vWF, the carrier 
protein of FVIII. 
 It has been hypothesised that bone marrow microvessel density increases due to neo-
chemotherapy
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vascularization in multiple myeloma(7, 8), which in turn results in an increase in vascular 
endothelium. Because endothelium is the main source of vWF in the circulation(9), this 
may explain increased vWF levels in multiple myeloma. However, it remains to be proven 
whether a direct relation of neovascularization with increased levels of vWF exists. Interes-
tingly, we analysed in retrospect a serum sample of 1 year before the diagnosis of multiple 
myeloma, and found a M-protein IgG-kappa of < 5 g/l, indicating a pre-existing MGUS. This 
was not accompanied with changes in FVIII:C or vWF:Ag levels compared to laboratory 
results obtained in the past. This demonstrates that the transformation of the MGUS to 
multiple myeloma resulted in the increased FVIII:C and vWF:Ag levels. 
 In our patient with inherited type 2A vWD, vWF:Ag and FVIII:C levels increased to nor-
mal levels at the time of diagnosis of multiple myeloma. vWF:RCo however remained low 
due to the underlying qualitative disorder of the vWF molecule. The multimeric pattern 
before and after start of therapy exhibited predominantly low molecular weight multimers, 
indicative of active proteolysis of vWF (Figure 1). The rate of proteolysis of vWF may be 
influenced by plasma ADAMTS13 activity which is a recently discovered metalloprotease. In 
our patient ADAMTS13 activity was 0.63 U/ml (normal 0.6-1.4) and did not change signi-
ficantly during treatment (at diagnosis of multiple myeloma 0.51, after treatment 0.51). In 
patients with vWD the bleeding tendency is not only related to vWF levels in plasma, but is 
also dependent on FVIII:C levels. This is examplified in patients with vWD treated with FVIII/
vWF concentrate, in whom FVIII:C levels are of main importance for clinical efficacy(10). 
Therefore we suggest that in our patient increased FVIII:C and vWF associated with multi-
ple myeloma resulted in relief of symptoms of vWD and that the successful treatment of 
multiple myeloma re-induced the bleeding tendency related to vWD. 
 We believe this to be the first report of a temporary relief of symptomatic vWD due 
to multiple myeloma. This report increases the understanding of hemostatic alterations in 
multiple myeloma, and may provide additional insight in the thrombotic tendency seen in 
these patients.
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INTRODUCTION
 In this journal we present a patient with Monoclonal Gammopathy of Uncertain Signifi-
cance (MGUS) who developed a serious life threatening complication due to massive expo-
sition to hydroxy-ethyl starch (HES) which was used as a plasma expander during repeated 
plasmapheresis.
CASE REPORT
 A 38-year-old woman had received stanozolol, cyclosporine, and frequent plasmaphe-
resis since 1997 because of IgG lambda monoclonal gammopathy with cryoglobulinemia-
associated ulcerating leukocytoclastic vasculitis. Initially, gelatin-based plasma expanders 
and pasteurized human albumin were used. Beginning in February 1999, plasma volumes 
were exchanged at a 1:1 ratio with undiluted 6% hydroxyethyl starch (HES, Fresenius-Kabi, 
Hamburg, Germany) because of the reported advantages of HES. 
 In August 2000, the patient developed severe weight loss, sensory polyneuropathy of 
the legs, and deteriorating eyesight. On examination, she was malnourished (body mass 
index, 17.6 kg/m2) with hepatosplenomegaly and ascites. She had normocytic anemia (he-
moglobin level, 7.1 mmol/L; mean corpuscular volume, 82 fL), thrombocytopenia (platelet 
count, 121 × 109 cells/L), low serum creatinine concentration (40 µmol/L [0.45 mg/dL]) 
and albumin level (26 g/L), and slightly elevated serum IgG level (15.9 g/L) and amino-
transferase levels (aspartate aminotransferase level, 62 U/L; alanine aminotransferase level, 
52 U/L). Magnetic resonance imaging of the brain revealed vasculitis of the choroid plexus 
with hydrocephalus and pituitary stalk edema. Histologic examination of bone marrow, skin, 
duodenal mucosa, liver, peritoneum, and dura mater and cytologic examination of the liver 
revealed massive infiltration with typical foamy macrophages (Figure). Hematoxylin-eosin, 
periodic acid Schiff, and oil red O staining showed empty vacuoles. Mycobacterium avium 
infection was ruled out. Enzyme analysis excluded Wolman, Niemann-Pick, and Gaucher 
diseases (all lysosomal storage diseases). Immunoelectron microscopy with polyclonal rab-
bit anti-HES serum, performed by Dr. S. Ständer (Westfälische Wilhelm-Universität, Mun-
ster, Germany), confirmed massive tissue storage of HES, especially in the vacuoles of the 
macrophages (Figure). Although plasmapheresis with conventional expanders was continu-
ed, the patient improved only slightly. After 8 months, a bone marrow biopsy still revealed 
108
massive foamy cell infiltration.
 Elimination of HES depends on distribution and back-diffusion from body tissues and 
metabolism (α-amylase), followed by urinary excretion(1). Persistent pruritus due to dose-
dependent and time-related skin deposits has been the most frequently reported complica-
tion of HES(2, 3). Skin deposits can be detected up to 4 years after the final administration 
of HES(2, 4). In our patient, HES exposure (130 L within 20 months) led to symptomatic, 
massive, diffuse tissue infiltration with HES-laden foamy macrophages.
Figure. Microscopic images. Top. Light microscopic image of a bone marrow biopsy revealing massive infiltration with 
CD68+ foamy macrophages. (Original magnification, ×200) Bottom. Immunoelectron microscopic image of endothelial 
cells with many small vacuoles (A) and two large vacuoles in the cytoplasm of histiocytes (B). The vacuoles express the 
characteristic peripheral amorphous material that is reactive for the anti-HES antibody (arrows). (Original magnification, 
×2200.) 
B
B
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ABSTRACT
background 
 Hydroxyethyl starch (HES) solutions have largely replaced conventional plasma expan-
ders such as human albumin and colloidal fluids. Only a few side effects have been reported 
and mainly concern pruritus or blood coagulation disorders. Excessive HES exposure can 
result in diffuse tissue storage and accumulation with foamy appearing macrophages which 
produce the enzyme chitotriosidase (CT). In case of massive tissue storage this enzyme 
activity can reach levels comparable to Gaucher’s disease. 
study design and methods 
 In this singel center retrospective analysis of eleven consecutive patients receiving large 
amounts of HES for chronic plasmapheresis we investigated plasma CT activity. Five pa-
tients receiving chronic intermittent plasmapheresis with conventional plasma expanders 
served as a control. Plasma CT activity was measured and plotted against creatinine clea-
rance. Where available bone marrow aspirate was analysed with light microscopy to detect 
foamy macrophages. One patient developed a lysosomal storage disease and was examined 
extensively. 
results 
 Conventional plasma expanders did not alter plasma CT activity. In patients with im-
paired renal function, frequent plasma replacement with HES resulted in an increase in 
plasma CT activity. In the patient with the acquired lysosomal storage disease massive tis-
sue infiltration with activated foamy macrophages was observed. The phagocytic capacity 
in this patient however did not seem to be altered. 
conclusion
 Patients with impaired renal function receiving large amounts of HES exhibit an increase 
in plasma CT activity. Because excessive HES exposure can result in an acquired lysosomal 
storage disease this should be avoided in chronic plasmaphereses.
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INTRODUCTION
 Since 1990, synthetic plasma expanders have replaced conventional, bovine gelatin-
based, plasma expanders because they lack the risk of prion transmission, have no bacterial 
or viral contamination and their use is associated with fewer adverse reactions. Hydroxy-
ethyl Starch products (HES, Fresenius-Kabi, Hamburg, Germany) are synthetic plasma ex-
panders that are frequently used to maintain and restore intravascular volume, stabilize 
hemodynamic conditions and improve tissue perfusion in ischaemic tissues(1-3). The most 
frequent reported side effects concern persistent pruritus of the skin and coagulation disor-
ders. Especially due to the blood coagulation disorder the clinical use of HES is limited and 
maximum daily doses of HES solutions have been recommended (25-50ml/kg)(4). Because 
of the reported advantages the use of HES products have also been proposed as a standard 
replacement therapy in apheresis. Data reporting on the side effects during long term use 
of HES products is however scarce and concern mainly therapy resistant pruritus of the 
skin due to tissue storage of HES. Large amount of HES however, can even result into mas-
sive tissue infiltration with activated foamy macrophages reflecting an acquired lysosomal 
storage disease(5). Activated foamy macrophages produce the enzyme chytotriosidase (CT) 
which can be used to monitor the effect of therapy in case of a lysosomal storage disease. 
In this study we analyzed plasma CT activity in eleven patients who had been exposed to 
large amounts of HES during frequent plamapheresis. 
PATIENTS & MATERIALS
patients and plasmapheresis technique
 Eleven patient from one center were collected who had received more than 10 liters of 
HES 200/0,5 (EloHAES ® 6%, Fresenius Kabi, Germany), during a sequence of plasmaphe-
reses using a single apheresis machine (GAMBO COBE type Spectra, Zaventem, Brussels, 
Belgium). During standard plasmapheris a total of 2500ml HES was used as a replacement 
during the procedure. When the plasma viscoicity was above two times normal a total of 
2000ml of HES was used together with 500ml normal saline (0.9% NaCl). The frequency 
of the procedures was based on the underlying disease in the patients and varied between 
once a week to three times a week. 
 Plasma samples were taken one month after cessation of plasmapheresis for determi-
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nation of plasma CT activity. Since elimination of HES products mainly depends on renal 
clearance, the estimated creatinine clearance was calculated from serum creatinine levels 
by the Cockcroft and Gault formula(6) and plotted against the plasma CT activity. When 
available bone marrow aspirate morphology was examined by light microscopy. To deter-
mine the effect of conventional plasma expanders on the plasma CT activity a group of five 
patients with Thrombotic Thrombocytopenic Purpura (TTP) who underwent frequent plas-
mapheresis with replacement by conventional gelatin based plasma expanders (2500ml per 
session, Gelofusine, Braun) were used as controls. Plasma samples in these control subjects 
were obtained prior to and after several sessions of plasmaphereses. Informed consent was 
obtained according to the declaration of Helsinki.
determination of plasma chitotriosidase
 Plasma CT activity was measured by incubating 5µl of EDTA plasma with 100µl of 0.022 
mM 4-methylumbelliferyl-β-D-N,N’,N’’-triacetylchitotriose (4 MU-chitotrioside; Sigma 
Chemical Co., St Louis, MO) as substrate in citrate/phosphate buffer (0.1/0.2 M), pH 5.2 at 
370 C, essentially as described previously(7).
microscopy
 Light-microscopic histological analysis of available tissue biopsies was performed using 
Hematoxylin-Eosin, Periodic Acid Shiff and Oil Red O staining. For electron microscopically 
investigation, biopsies were fixed in Karnovsky’s fixative, postfixed in 1% osmium tetroxide, 
dehydrated, and embedded in Epon. Semi-thin sections were cut with glass knives on an 
ultramicrotome and stained with toluidine blue. For routine electron microscopy, ultra thin 
sections were cut with diamond knives, mounted on copper grids, and stained with uranyl 
acetate and lead citrate.
 One patient received excessive amounts of HES and was therefore extensively exa-
mined. In this patient various tissue biopsies were obtained and tissue storage was confir-
med with immuno-electron microscopy utilizing polyclonal rabbit anti-HES antibodies(8). 
Pre-incubation with millipore filtered 4% ovalbumin for 10 minutes was followed by over-
night incubation with the primary polyclonal antibody (diluted 1:4000 in phosphate-buf-
fered saline: PBS)(9) . The ultra-thin specimens were then examined using a Philips CM10 
electron microscope. Fluorescent-activated cell sorter (FACS) analysis of peripheral blood 
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mononuclear cells (PB-MNC’s) was performed with a FACS Calibur Becton-Dickinson (BD) 
using the following monoclonals: CD15, CD16, CD13, HLADR, CD11b and CD45 (BD, San 
Jose, California). For this purpose cryopreserved PB-MNC’s were sorted by FSC and SSC. 
(DIVA BD, San Jose, California). The phagocytic activity was tested using Phagotest (Orpe-
gen Pharma, Heidelberg, Germany). In short, 100 µl whole blood or thawed peripheral blood 
MNC’s were incubated for 0,10, 20 and 30 minutes with opsonized E-Coli FITC. After incu-
bation cells were put on ice water and stained with quenching solution to quench bacteria 
outside the phagocytic cell. DNA staining was performed to discriminate between bacteria 
and phagocytes. The percentage of cells with phagocytosed bacteria was measured using a 
FACS Calibur (BD, San Jose, Ca).
STATISTICAL ANALYSIS
 This study was a retrospective analysis of eleven consecutive patients receiving large 
amounts of HES for chronic plasmapheresis in our hospital. Although the sample size was 
small, when possible statistical analysis was performed using the one-tailed Wilcoxon sig-
ned rank test and the one-tailed Spearman correlation coefficient test. 
RESULTS
plasmapheresis with hes
 The characteristics of the patients are summarized in Table 1. Plasmaphereses were per-
formed in six patients with hematological disorders, three patients with neurological dis-
orders, one patient with a dermatological disorder and one patient with a benign recurrent 
intrahepatic cholestasis syndrome. 
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 In patients with impaired creatinine clearance (patients 1 to 6), a high HES exposure 
(liters/month) was associated with an significant increase in plasma CT activity above the 
normal range (Wilcoxon signed rank test P=0,02 Spearman correlation coefficient 0,8586). 
In patients with a normal creatinine clearance (7 to 11) however, high doses of HES were 
not associated with a plasma CT activity above the upper normal limit. Although the sam-
ple size is small, these results suggest that plasma CT activity is increased in patients with 
impaired renal function who were exposed to a high dose of HES. The relation between 
plasma CT activity and renal function is plotted in Figure 1. 
Figure 1. Plasma CT level and renal function in patients with () and without (•) HES exposition. Patients with foamy 
macrophages in bone marrow aspirate (). Normal plasma CT level range: 4-195 nmol/ml/hr.
  Bone marrow aspirates were available for examination in five patients (patients 1, 2, 4, 
6 and 8). Despite normal plasma CT activity in two of these patients, foamy macrophages 
were observed in five patients even after a cumulative HES dose of less than 10 liters. 
Patient 1 received the highest cumulative dose and exhibited massive bone marrow infil-
tration with foamy macrophages (Figure 3). This patient developed a severe acquired lyso-
somal storage disease (ALSD) with plasma CT activity within the range of Gaucher disease 
(GD). The extent of marrow infiltration with foamy macrophages in the other patients was 
however much less than in the patient with the ALSD.
plasmapheresis with conventional expanders
 Plasma CT activity was within normal range in all patients in the control group. In these 
subjects, frequent plasmaphereses with conventional expanders did not alter the plasma 
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CT activity significantly (Table 1). These results support the hypothesis that plasmapheresis 
with conventional expanders do not alter plasma CT activity. 
Acquired lysosomal storage disease 
 One patient (no 1) received a high dose of HES (130 liters) and developed a lysosomal 
storage disease. This patient, who was an outlier compared to the other patients, was diag-
nosed suffering MGUS with type IgG kappa cold agglutinin disease. Chronic plasmaphereses 
was started because of severe disabling skin necrosis due to therapy resistant leucocyto-
clastic vasculitis. At that time plasma CT activity was normal and a bone marrow biopsy 
revealed no foamy macrophages at all. This patient received during the first six months of 
phereses the combination of gelatin based plasma expander (36.5 liters) and pasteurized 
human albumin (25.5 liters, Cealb, Sanquin) without altering plasma CT activity (Figure 2). 
The following twenty months a cumulative dose of 166,5 liters of Gelofusine (Braun) was 
used as a single agent. Again plasma CT activity was unaltered and remained normal (47 
nmol/h/ml). A bone marrow biopsy performed at that time did not show foamy macro-
phages. Next, the conventional plasma expanders were replaced by HES. Serum CT activity 
increased exponentially and reached the level comparable to that found in Gaucher Disease 
after a cumulative dose of 100 liters over a time period of ten months (Figure 2). 
Figure 2. Plasma chitotriosidase level in a patient with acquired lysosomal storage disease following plasmapheresis.
 At the same time this patient developed symptoms of a lysosomal storage disease i.e., 
severe weight loss, organomegaly with ascites, myelofibrosis, polyneuropathy and hydro-
cephalus with vasculitis of the choroid plexus and pituitary stalk edema as a result of exces-
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sive tissue infiltration with foam cells (Figure 3). Bone marrow aspirate morphology confir-
med these cells to be of macrophage origin. Similar massive foamy macrophages infiltration 
was observed in biopsies taken from the skin, liver, duodenal mucosa, peritoneum and dura 
mater. Typical HES storage within the vacuoles in the cytoplasm of skin macrophages and 
endothelial cells was confirmed with immuno-electron microscopy. In this patient, cultu-
red fibroblasts exhibited a normal alpha-glucosidase activity. After confirming the relation 
between excessive HES exposition and ALSD, plasmapheresis was continued with a change 
to conventional expanders in order to facilitate a gradual clearance of HES. This approach 
did not result in a significant decrease of plasma HES concentrations or plasma CT activity 
(Figure 2). One year after cessation of HES, the plasma CT activity was still within the range 
of GD (higher than 7000 nmol/hr/ml) and in the bone marrow morphology massive foamy 
macrophage infiltration was still present. 
 In this patient, the phagocytic capacity of monocytes (85%) and granulocytes (95%) 
after thirty minutes was within normal limits. However, the thawed peripheral blood mo-
nonuclear cells (PB-MNC’s) contained a subpopulation of granulocytes, which was absent 
in a control subject (Figure 4). These cells were resistant to freezing and thawing and had 
a lower phagocytic capacity (max 38% after 20 minutes). On light microscopy however, 
these cells had a normal morphology without the typical foamy appearance. 
Figure 3. Light microscopic image of liver (A, 200x), peritoneum (B, 400x) and the duodenal mucosa (C, 200x) of the 
patient with the acquired lysosomal storage disease.
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Figure 4. FACS staining of peripheral blood mononuclear cells revealing the extra population (Panel A) in the SALSD patient.
 
DISCUSSION
 Chitotriosidase (CT) is an enzyme that plays a role in the degradation of chitin-contai-
ning pathogens(10). In humans this enzyme is almost exclusively synthesized by activated 
macrophages(10). Chitotriosidase is a very stable enzyme and its activity can be tested in 
cryopreserved plasma samples for up to 8 years(11). The chitotriosidase activity increases 
with age and normal values range from 4 to 195 mmol/hr/ml(11). Elevated plasma CT levels 
serve as a diagnostic hallmark in patients with GD and the plasma level is correlated with 
the extent of tissue infiltration by foamy macrophages(7). Elevated plasma CT activity ho-
wever, is not correlated with specific clinical signs and symptoms(11). Our study supports 
the assumption that plasma CT activity is not influenced by plasmaphereses with con-
ventional expanders such as modified gelatin or human albumin. This suggests that these 
conventional expanders are not stored into macrophages in tissues. 
 HES is a synthetic colloid plasma volume expander which has been used as an alter-
native for albumin and gelofusine in patients undergoing plasma exchange. The kinetics of 
its elimination is complex. Smaller molecules (Mw<50.000 Da, T½ of 0,4 to 6,4 days) are 
readily excreted in the urine. Elimination of larger molecules depends on: (a) distribution 
into body tissues; (b) back-diffusion from tissues into intravascular spaces; and (c) metabo-
lism by α-amylase in blood, tissues, and the reticuloendothelial system, followed by urinary 
and biliary excretion with a T½ ranging from 72 to 240 days(12, 13). Tissue storage in cells 
of various organs, predominantly affecting the mononuclear phagocyte system (MPS) has 
been demonstrated previously(14). This is a dose-dependent and time related phenomenon 
Panel A Panel B
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and marked signs of storage can be detected up to 4 years after the final administration(15, 
16). Patients on hemofiltration or dialysis exhibit an even more prolonged half-life due to 
incomplete HES elimination(17). In these patients, even small quantities of HES can cause 
hepatosplenomegaly, portal hypertension and ascites(18).
 A relation between HES storage in macrophages and plasma CT activity has not yet 
been documented. Our data suggest that chronic intermittent administration of HES during 
plasmapheresis in patients with impaired renal function will result in tissue storage, especi-
ally within the MPS. These macrophages are unable to further digest the HES molecules. The 
continuous accumulation within the vacuoles will result in the foamy appearance. These 
stressed macrophages produce CT through a mechanism that is yet unknown. However, 
when sufficient tissue infiltration with activated foamy macrophages occurs, this will result 
in an increase of plasma CT activity. Since two patients (pt 5 & 6) receiving high dose of 
HES exhibited only a slightly elevated CT activity additional factors such as the time period 
in which the large amount of HES was administered may also be of importance. These pa-
tients (pt 5 & 6) received their HES during a prolonged period of time (1,1 – 1,4 ltr/month) 
whereas the other patients were exposed to higher doses over a shorter period of time (2,2-
10 ltr/month). However, based on the limited number of patients this remains speculative. 
 In GD the level of plasma CT activity reflects the extent of tissue infiltration with acti-
vated foamy macrophages. The first patient exhibited massive tissue infiltration with foamy 
macrophages whereas in bone marrow biopsies of the other patients (when available), mo-
derate infiltration was observed. We therefore suggest that the CT activity can serve as an 
indirect diagnostic tool to monitor the extent of tissue infiltration with HES. Because there 
is no evidence regarding this assumption we cannot confirm this statement and further in 
vitro studies exposing cultured macrophages to HES might be helpful in confirming this hy-
pothesis. Since plasma CT activity directly reflects the extent of foamy macrophage infiltra-
tion in lysosomal storage disease, we suggest that in case large amounts of HES have been 
administered (> 30 liters) and plasma CT activity rises above the upper limit of normal, 
HES substitution should be discontinued. Brecher reviewed the literature on the use of large 
volumes of HES and found that is was well tolerated without any serious complications(2). 
However, in one case the patient developed normocytic normochronim anemia and bone 
marrow replacement with “lipid laden” macrophages(19). 
 One patient developed a severe ALSD due to massive tissue infiltration with these 
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foamy macrophages as a result of chronic plasmaphereses with HES (cumulative dose: 130 
liters within 20 months). This resulted in severe weight loss, organomegaly with ascites, 
myelofibrosis, polyneuropathy and hydrocephalus with vasculitis of the plexus choroideus. 
Interestingly this patient did not complain of persistent pruritus, which has been reported 
to be the only major side effect of HES administration. This could be due to the polyneuro-
pathy that she developed due to the massive tissue storage. Retrospective analysis of the 
plasmapheresis history of this patient revealed that conventional plasma expanders did not 
alter the plasma CT activity at all. After a cumulative dose of 20 liters of HES, plasma CT 
activity increased exponentially to finally reach the level of GD. When the relation between 
HES storage and plasma CT activity was confirmed, HES re-infusion was stopped, and plas-
maphereses were continued with conventional expanders. Although this corrective action 
resulted in a clinical improvement, plasma CT activity remained high even after two years. 
Furthermore, a bone marrow biopsy performed after one year still revealed massive infiltra-
tion with foamy macrophages. 
 Recent clinical investigations suggest that the phagocytotic capacity and signal trans-
duction of monocytes is unaltered by intracellular colloid storage after incubation with 
HES resuscitation fluids in vitro(20-23). However, there is no literature regarding the effect 
of long-term in vivo exposure to HES and the effect on the PB-MNC’s. In our patient, the 
phagocytic capacities of the peripheral blood monocytes and granulocytes were within 
normal limits. However, thawed peripheral blood MNC’s contained an extra population 
(CD15+, CD16+, CD13+, HLADR negative, CD11b+ and CD45 dim), which was absent in 
control patients. These granulocytes were resistant to freezing and thawing and had a lower 
phagocytic capacity. Light microscopic analysis of these granulocytes revealed no typical 
vacuolization. We assume that these granulocytes had already phagocytosed small amounts 
of HES before migrating into the tissues, and therefore exhibit a reduced phagocytic activity 
in the phagocytic test. In contrast, unaffected phagocytosis of HES by monocytes/macro-
phages in the tissues may result in prolonged storage of HES within the vacuoles, ultimately 
leading to the foamy appearance of these macrophages. The possible mechanism of the 
acquired lysosomal storage disease might be that HES molecules can only be hydrolysed 
and degraded by the enzyme alpha-glycosidase into smaller molecules. Urinary elimination 
is biphasic with an initial half-life of 3-4 days (small molecules) and of 48 days (larger mo-
lecule hydrolization)(24). The remaining HES molecules are resistant to cleavage and can 
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be detected several months after transfusion. These larger molecules are phagocytosed and 
stored in macrophages. Excessive exposure to these cleavage resistant HES molecules may 
result in extensive tissue accumulation with foamy macrophages. This may affect various 
organs and results in organ dysfunction and an acquired lysosomal storage disease. We 
believe that all forms of HES products despite its various forms, can result in tissue accu-
mulation when substituted in large amounts(25).
 
CONCLUSION
 We conclude that in patients with pronounced tissue accumulation and infiltration with 
HES containing foamy macrophages, plasma CT activity might serve as a diagnostic tool to 
monitor the extent of tissue infiltration. Furthermore, chronic intermittent plasmapheresis 
with excessive replacement with HES products might result in a severe ALSD. Based on 
this severe side effect and the reported effects of HES on blood coagulation(26)and renal 
function(27) we believe that HES products should be used with caution during chronic 
plasmapheresis, especially in patients with impaired renal function. 
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SUMMARY
 Thrombo-embolic complications occur frequently in patients with malignancy. In pa-
tients with multiple myeloma, incidences of up to 28 percent are reported. Most throm-
boembolic complications are observed during the induction phase of multi-agent chemo-
therapy. The combination of antracyclines and dexamethasone with anti-angiogenic drugs 
such as thalidomide, increases the incidence considerably. Although several studies have 
been performed on this topic in the past years, the mechanism of the increased thrombotic 
risk in patients with multiple myeloma remains largely unraveled. 
 The main objective of this thesis was to analyze different aspects of the hemostatic sys-
tem in patients with multiple myeloma in order to increase our knowledge of hemostatic 
abnormalities and to determine their role in the development of venous thrombo-embolic 
complications. 
 The current literature on the relationship between multiple myeloma and thrombosis 
was summarized in chapter 1. In addition the aims of the studies described in this thesis 
were mentioned.
  The first aim was to analyse baseline hemostatic variables in untreated patients with 
multiple myeloma. The results are presented in chapter 2. A total of 135 patients with 
newly diagnosed multiple myeloma were studied for this analysis. Factor VIII:C and von 
Willebrand Factor antigen (vWF:Ag) were strongly elevated. A strong correlation between 
vWF and FVIII:C levels was observed. Furthermore, vWF:Ag levels correlated strongly with 
vWF collagen binding (vWF:CB) and ristocetin-cofactor activity (vWF:RCo). Factor VIII and 
vWF levels correlated with the prognostic International Scoring System (ISS) disease stage 
with the highest levels in stage III. When staged according to the Salmon and Durie clas-
sification system, the correlation with disease stage was less clear. Protein S levels were in 
the low normal range in patients with multiple myeloma and were significantly lower in the 
higher ISS stages compared to stage I. Other coagulation parameters, including antithrom-
bin, fibrinogen and D-dimer levels, were not significantly different compared to healthy 
volunteers. During the course of treatment, thrombo-embolic complications were observed 
in 10% of the patients and occurred most frequently during induction chemotherapy. Ho-
wever, no single prothrombotic abnormality at baseline was significantly associated with 
the development of a thrombo-embolic complication. In conclusion, this study indicates 
that various prothrombotic abnormalities occur in patients with newly diagnosed untreated 
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multiple myeloma, such as strongly increased vWF and Factor VIII levels, and a decrease of 
protein S levels. Furthermore, the level of these coagulation variables seem to correlate with 
the ISS stage of disease.
 Subsequently we analyzed coagulation variables during several phases of treatment in 
patients with multiple myeloma who were treated with multi-agent chemotherapy fol-
lowed by high dose melphalan (HDM) with autologous stem cell transplantation (ASCT). 
The results are presented in chapter 3. Response to treatment was assessed after induction 
therapy and 3 to 6 months after autologous stem cell transplantation. At the end of treat-
ment, most patients showed a remission (85%), of which 14% complete and 86% partial. 
We compared levels of various coagulation factors during and after treatment in the total 
patient group. FVIII:C and vWF:Ag levels showed a parabolic course during the treatment 
phases with the maximal values after induction treatment. FVIII and vWF levels at the end 
of treatment, after high dose melphalan followed by autologous stem cell support, were 
significantly decreased compared to the levels during treatment. Fibrinogen levels signifi-
cantly increased during treatment and remained elevated after the HDM with ASCT. In the 
linear mixed-effects analysis of the three time points, fibrinogen levels were significantly 
different between the VAD and TAD group with a higher increase in the TAD group ver-
sus the VAD group. Although antithrombin, protein C or protein S levels increased slightly 
during induction chemotherapy, these levels remained within the normal range. There was 
no relationship between coagulation parameters before, during and after treatment and the 
development of VTE. In conclusion, this study shows that there is a significant increase in 
the levels of vWF, FVIII:C and fibrinogen during the induction therapy of multiple myeloma 
and that these levels decrease after the ASCT. 
 In chapter 4 the plasma fibrinolytic potential was measured in 77 patients with multiple 
myeloma patients who were treated with multi-agent chemotherapy followed by HDM and 
ASCT. Fibrinolysis was assessed before, during and after chemotherapeutic treatment. These 
patients received induction therapy with either VAD of TAD. There was no significant diffe-
rence in clot lysis time between age matched control subjects and the patients prior to the 
start of induction chemotherapy. However, there was a significant increase of clot lysis time 
during both VAD and TAD as compared to clot lysis times of the control subjects, indicating 
the development of hypofibrinolysis during chemotherapy. After high dose melphalan with 
autologous stem cell support, the clot lysis times normalized and were similar to the control 
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group in both the VAD and TAD treated patients. It is concluded that hypofibrinolysis, which 
is known to be associated with VTE (1), occurs during induction chemotherapy in multiple 
myeloma patients. 
 Tissue factor is the principal initiator of the coagulation cascade and can be demonstra-
ted on circulating microparticles that are released from cells following activation or during 
apoptosis. Recent studies have indicated an association between microparticle Tissue Factor 
(MP-TF) activity and thrombosis in adenocarcinoma(2). We analyzed MP-TF activity in mul-
tiple myeloma patients who were treated with multi-agent chemotherapy and presented 
this in chapter 5. Prior to the start of chemotherapy, the median MP-TF activity level in 
multiple myeloma was significantly higher than in healthy volunteers (17.8 fM Xa/min [IQR 
8.8-32.8] versus 4.7 fM Xa/min [IQR 2.3-6.6], P<0.001). Lambda type multiple myeloma 
exhibited higher MP-TF activity than kappa type multiple myeloma. The severity of disease, 
according to the Salmon and Durie criteria and the prognostic ISS score was not correlated 
with the levels of MP-TF activity. MP-TF activity decreased significantly after three courses 
of induction chemotherapy and the reduction was irrespective of the type of induction 
chemotherapy used. VTE incidence was 8% in the VAD treated patients, 11% in the TAD 
treated patients and 7% in the PAD treated patients. In patients who developed VTE, MP-
TF activity remained increased after the induction therapy. In conclusion, MP-TF activity 
levels are increased in patients with untreated multiple myeloma and decrease significantly 
after induction chemotherapy. Our results may indicate that persistently increased MP-TF 
activity levels in plasma of multiple myeloma patients during induction treatment may 
be of pathogenetic importance in the development of VTE. Larger studies are required to 
investigate whether increased MP-TF activity levels are causally related to the occurrence 
of VTE in multiple myeloma patients.
 The prevention of VTE, especially in multiple myeloma patients receiving multi-agent 
chemotherapy in combination with anti-angiogenic drugs is still a major issue and the op-
timal antithrombotic regime in multiple myeloma patients receiving induction treatment 
has yet to be established. We performed a prospective study to investigate the prevention 
of VTE with the low molecular weight heparin (LMWH) nadroparin in patients receiving 
multi-agent chemotherapy in combination with thalidomide included in the HOVON-50 
study and presented the data in chapter 6. In this large prospective intervention study we 
observed a VTE incidence of 10% in the patients treated with thalidomide, dexamethasone 
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and doxorubicin who received prophylactic nadroparin. This incidence is comparable with 
the incidence of VTE during intensive chemotherapy in newly diagnosed multiple myeloma 
patients, without the use of thromboprophylaxis reported previously in the literature. In our 
prospective study the incidence of VTE in patients receiving VAD without thrombo-prop-
hylaxis was 5%. It can be concluded that the use of LMWH is a safe when patients receive a 
thalidomide combination-based chemotherapeutic regimen and that the incidence of VTE 
is reduced to an incidence comparable to standard chemotherapy with antracyclin. 
 Recent reports suggest an increased VTE incidence in patients with other malignant 
plasma cell disorders, including AL-amyloidosis (VTE incidence 7%) and Monoclonal Gam-
mopathy of Undetermined Significance (MGUS) (VTE incidence 11%) (3-6). We therefore 
analyzed coagulation variables in patients with other paraprotein producing B-cell disorders, 
such as MGUS, AL amyloidosis and Waldenstrom’s Macroglobulinemia (WM). The results 
are presented in chapter 7. In this study we observed that vWF and factor VIII levels are not 
only increased in patients with multiple myeloma, but also increased in the other plasma 
cell disorders (PCD), with the highest levels in patients with AL amyloidosis. Protein S acti-
vity was within the lower range of normal in all forms of PCD, and no significant difference 
between the various groups was found. In patients with AL amyloidosis, fibrinogen levels 
were significantly higher compared to control subjects and the other PCD. In conclusion, 
we observed similar coagulation abnormalities in patients with different PCD, as previously 
found in patients with multiple myeloma. The highest levels of FVIII and vWF were observed 
in patients with AL amyloidosis. 
 In chapter 8 we studied a patient with inherited type 2A von Willebrand disease (vWD) 
who developed multiple myeloma. This study shows that the clinical phenotype of vWD can 
be altered by the multiple myeloma associated increase of vWF and FVIII. In this patient 
vWF:Ag and FVIII:C levels increased to normal levels at the time of diagnosis of multi-
ple myeloma and resulted in a temporary relief of bleeding symptoms especially during 
chemotherapy. vWF activity levels however remained relatively low due to the underlying 
qualitative disorder of the vWF molecule. The multimeric pattern before and after start of 
therapy exhibited predominantly low molecular weight multimers, indicative of active pro-
teolysis of vWF. Treatment of multiple myeloma resulted in a decrease of FVIII and vWF to 
pre-existing levels and re-induced the bleeding tendency related to vWD in this patient. In 
conclusion this observation stresses the clinical importance of coagulation factor changes 
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in altering the hemostatic balance in patients with multiple myeloma. This provides more 
insight in the pathogenetic mechanism, underlying the VTE complications in multiple my-
eloma patients. 
 In chapter 9 a patient with therapy resistant ulcerating vasculitis due to a MGUS rela-
ted cryoglobulinemia was studied. In this patient, chronic plasmapheresis with the plasma 
expander hydroxy-ethyl starch (HES) was initiated because of severe disabling skin necrosis 
due to therapy-resistant leucocytoclastic vasculitis. This patient developed a rare and severe 
complication as a result of frequent plasmapheresis with HES. This resulted is diffuse sys-
temic infiltration with foamy appearing activated macrophages and plasma chitotriosidase 
(CT) activity within the range of Gaucher’s disease. In an additional study in 15 patients 
receiving chronic intermittent administration of HES during plasmapheresis we found that 
in patients with impaired renal function, this will result in tissue storage, especially within 
the mononucleair phagocyte system. Although the sample size of our study is small, these 
results suggest that plasma CT activity is increased in patients with impaired renal function 
who were exposed to a high dose of HES. It can be concluded that the administration of 
large amounts of HES as a plasma expander in plasmapheresis can result in tissue accumu-
lation of HES especially in patients with impaired renal function. 
GENERAL DISCUSSION
thrombo-embolic events in multiple myeloma
 Multiple myeloma accounts for approximately 10% of all hematologic malignancies 
with an annual incidence of 3-4 cases per 100,000 and is still considered incurable. The 
introduction of high-dose therapy with stem cell support and new antimyeloma agents 
has improved the overall survival from a median of 24-30 months obtained with conventi-
onal therapy to over 5 years nowadays. In recent years it has become evident that a major 
complication observed in patients with multiple myeloma is the development of venous 
thrombo-embolism (VTE). The overall incidence reported in untreated patients with multi-
ple myeloma is appoximately 10% after the initiation of standard multi-agent chemothe-
rapy, such as VAD or thalidomide(6, 7). This incidence of VTE strongly dependends upon the 
disease status (newly diagnosed, refractory or relapsing) and the kind of treatment the pa-
tient receives. When the anti-angiogenic drug thalidomide is added to chemo-therapeutic 
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regimens, VTE incidences up to 28% have been reported(8). This might be explained by 
the observation that the combination of doxorubicin with thalidomide may induce endo-
thelial cell dysfunction(9, 10). In refractory and/or relapsed patients the incidence of VTE 
is lower. When treated with conventional chemotherapy the overall VTE incidence is 5% 
and increases to 12% when thalidomide is added to the regimen. The recently introduced 
thalidomide derivate lenalidomide is also associated with an increase in VTE risk, especially 
when combined with dexamethasone(11-14). On the other hand, the newly introduced 
proteasome inhibitor bortezomib is associated with a lower incidence of VTE(15, 16). The 
low VTE incidence during bortezomib treatment may in part be explained by the fact that 
bortezomib has so far predominantly been used in refractory patients, who, as mentioned 
above, have a lower incidence compared to previously untreated myeloma patients. Howe-
ver, in vivo and in vitro studies have shown an inhibitory effect of bortezmib on platelet 
aggregation induced by ADP which suggests an antithrombotic effect of bortezomib and 
might therefore also explain the lower incidence of VTE in these patients during multi-agent 
chemotherapy(16, 17). In our studies the incidence of VTE in a cohort of newly diagnosed 
multiple myeloma patients during chemotherapeutic treatment was 10%, which is similar 
to the data presented in the literature(18). The VTE incidence observed in our patients re-
ceiving the combination of thalidomide and multi-agent chemotherapy was also 10%. This 
lower incidence than previously reported in the literature, is due to the LMWH prophylaxis 
that these patients received during therapy(19). 
changes in the hemostatic system in multiple myeloma
 Several independent risk factors have been reported in the literature to be associated 
with the development of VTE in multiple myeloma patients, including newly diagnosed 
status; the use of thalidomide/doxorubicin regimen; presence of chromosome 11 abnorma-
lities; light-chain disease and elevated C-reactive protein (20).
 Multiple myeloma is also associated with a hypercoagulable state. Treatment with che-
motherapy with or without anti-angiogenic agents may aggravate this hypercoagulable 
state and may trigger the development of thrombosis. Previously reported factors that may 
contribute to the increased risk of VTE include acquired abnormalities in platelet function, 
secondary hemostasis and fibrinolysis. For instance acquired resistance to APC has been 
associated with the risk of VTE in multiple myeloma patients(20, 21 - 26). The fact that bor-
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tezomib treatment is associated with a lower risk of VTE may be due to the anti-aggregating 
effect on platelet function(17, 27, 28). In a recent study by Zangari et al, platelet function 
was assessed pre- and post infusion of bortezomib. They found a significant decrease in 
epinephrine and ristocetin induced platelet aggregation. Also the expression of P-selectin at 
the platelet surface was decreased after bortezomib infusion (29). The addition of high dose 
dexamethasone may also be of pathogenetic importanve in the occurrence of VTE, since it 
has been shown that high dose dexamethasone increases circulating P-selectin and vWF 
and may also result in higher FVIII levels(30).
 Recently, high plasma levels of soluble P-selectin in solid cancer-associated VTE was 
found to be a possible predictor for the development of VTE(31). The role of P-selectin in 
multiple myeloma associated VTE however has not yet been studied.
  In this thesis we have shown that in newly diagnosed multiple myeloma, before tre-
atment is initiated, several coagulation abnormalities are observed. During the induction 
phase with multi-agent chemotherapy these abnormalities in both coagulation and fibri-
nolysis deteriorate substantially, resulting in an even more severe hypercoagulable state(25, 
32). The alterations in secondary hemostasis observed in our studies in a large group of MM 
patients are depicted in Figure 1. 
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 Figure 1 Alterations in the secondary haemostasis in multiple myeloma at diagnosis (red) and after multi-agent chemo-
therapy (blue).
  Although the data from our studies, as well as the data recently presented in the lite-
rature, provide more insight into the coagulation abnormalities in patients with multiple 
myeloma, no single coagulation variable can yet be used to predict whether a patient will 
develop a VTE. We believe that the altered coagulation abnormalities in combination with 
other well known risk factors such as immobility, surgery and indwelling central venous 
catheters, may result in an additionally increased risk for VTE. Although we included a large 
cohort of multiple myeloma patients for our longitudinal coagulation studies, the number 
of patients that developed VTE was limited. Therefore we were not able to establish an 
association between coagulation disturbances and the development of VTE. Our studies 
however, show that increased FVIII and vWF levels, hypofibrinolysis and increased MP-as-
sociated TF activity occurs in patients with multiple myeloma and that this may contribute 
to the hypercoagulable pro-thrombotic state and the development of VTE. Larger studies 
however, are needed to provide more insight in the mechanism of thrombosis and the pos-
sible predictive role of the above-mentioned variables in multiple myeloma patients. 
prevention of Vte in multiple myeloma
 The recognition of a hypercoagulable state in newly diagnosed multiple myeloma, es-
pecially during multi-agent chemotherapy in combination with anti-angiogenic drugs, has 
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led to the introduction of prophylactic anticoagulant therapy. There is however, still debate 
regarding the optimal antithrombotic regimen in multiple myeloma patients receiving in-
duction treatment with anti-angiogenic drugs. The results of various thromboprophylactic 
regimens have recently been reported (Table 1) and several trials are ongoing to investigate 
which regimen is optimal to prevent VTE in patients with multiple myeloma treated with 
multi-agent chemotherapy. 
Thal= Thalidomide, Bort= Bortezomib, Dex= Dexamethasone, chemo= multi-agent chemotherapy, Len= lenalidomide, 
LMWH= low molecular weight heparin, LD-VKA= low dose vitamin K antagonist, VKA= vitamin K antagonist (references) 
 Intervention with vitamin K antagonists seems reasonable because of the observed al-
terations in secondary hemostasis in multiple myeloma. However, a fixed low dose warfarin 
(1mg/day) is insufficient in reducing the VTE incidence(43). Full-intensity warfarin (target 
INR: 2-3) or low molecular weight heparin, reduces the risk of thrombo-embolic complica-
tions, but may be associated with increased bleeding(19, 34, 41, 52). In a sub study of the 
HOVON-50 study LMWH was used to prevent VTE in patients receiving a thalidomide-
based regimen as induction therapy. This resulted in a VTE incidence of 10%, which is similar 
to that reported in the literature when multi-agent chemotherapy was given in combina-
tion with thalidomide and thromboprophylaxis(19). Aspirin is effective in preventing arterial 
thrombosis (e.g. myocardial infarction, stroke) and it has been recently been suggested that 
aspirin is safe and effective in preventing VTE in multiple myeloma(24, 26, 32). In refractory 
therapy none aspirin lmWh ld-VKA VKA
newly diagnosed mm
Melphalan/thal/prednisone 12-21(33-35) 3-7.1(33, 34)
Thal/Dex 12-26(36-41) 7(41) 25(41) 7-13(36-38, 41)
Thal/chemo (+antracyclines) 16-27(8, 42) 9-15(19, 43) 31(43) 12(44)
Thal/chemo (+antracyclines) 34(45) 24(45)
Len/Dex 75(46) 3-18.5(46-48)
Len/Dex (low dose dex) 5.4(47)
Melphalan/prednisone/Len 2.1(34)
Len/cyclophosphamide/Dex 16(49)
thromboprophylaxis
table 1. Vte incidence (%) with thromboprophylaxis during treatment of mm
previously treated/relapsed/refractory mm
Thal/chemo (+antracyclines) 15(50) 10(15)
Bort/Thal/chemo (+antracy-
clines)
0(15)
Chemo (+antracyclines) 9(51)
138
patients receiving lenalidomide in combination with dexamethason aspirin (80-325mg/
day) reduced the incidence of VTE significantly(47). Recent clinical trials confirmed the 
successful use of aspirin as thromboprophylaxis in untreated multiple myeloma patients re-
ceiving multi-agent therapy(22, 34, 53). In a randomised controlled trial, which was recently 
presented, in which various thalidomide containing chemotherapeutic regimens were used, 
LMWH was equal to aspirin or low dose warfarin in preventing VTE. However LMWH was 
associated with fewer bleeding complications(54). So far, except for the study presented by 
Palumbo et al, few data are available regarding the use of thromboprophylaxis during treat-
ment with the recently introduced new anti-myeloma agents such as bortezomib and lena-
lidomide. However, based on the available data, bortezomib seems to be associated with a 
low VTE incidence(55). Furthermore, the combination of lenalidomide with bortezomib wit-
hout thromboprophylaxis is also associated with a low VTE incidence(54). Perhaps the pos-
sible inhibitory effect of bortezomib on platelet aggregation might provide some protection 
by interfering with primary hemostasis, as mentioned above(17). This phenomenon and its 
clinical implication need further clinical investigation. More prospective controlled trials 
should be conducted to answer the question which thromboprophylaxis should be used 
in various chemotherapeutic regimens as well as the duration of prophylaxis. Recently Pa-
lumbo et al presented their recommendations regarding the choice of thromboprophylaxis 
in myeloma patients receiving thalidomide or lenalidomide in combination with steroids 
of chemotherapy(56). The choice should be tailored to the presence of standard individual 
risk factors that may increase the risk of VTE (obesity, age, history of VTE, central-venous 
catheter, comorbidities, surgical procedures and inherited thrombophilia), myeloma related 
risk factors (previously untreated myeloma and/or hyperviscosity) and therapy related risk 
factors (dexamethasone and/or doxorubicin). Based on our observations and these recom-
mendations aspirin could be used in low-risk patients, such as those with no risk factor 
or one individual/myeloma-related risk factor. In these patients interfering with primary 
hemostasis might be sufficient to prevent VTE. In the presence of more than one individual 
or myeloma-related risk factor, a more intensive thromboprophylaxis is warranted. In these 
patients LMWH should be recommended especially when high-dose dexamethasone or 
doxorubicin or multiagent chemotherapy are administered. In patients who receive multi-
agent chemotherapy in combination with bortezomib, the recommendations are still un-
clear and need to be investigated further. 
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future studies
 A variety of coagulation abnormalities in multiple myeloma patients have now been 
characterized that contribute to a state of hypercoagulability. However, a direct relation-
ship with the development of VTE is not yet established. Therefore larger studies are re-
quired. Instead of focussing on single prothrombotic changes in MM patients , future studies 
should include global coagulation tests to assess the combined effect of these coagulation 
abnormalities. For this purpose thrombo-elastography, thrombo-elastrometry and throm-
bin generation assays can be used. Furthermore, the relationship between coagulation and 
inflammation could be further characterized, since in general inflammation also plays an 
important role in the development of thrombosis(57). Genetic predisposition due to single 
nucleotide polymorphisms (SNPs) or certain haplotypes may also be a risk factor for the de-
velopment of thrombosis in VTE patients. A recent studie in a large cohort of multiple my-
eloma patients treated with thalidomide has identified several SNPs in genes and pathways 
important in drug transport, drug metabolism, DNA repair and cytokine balance that were 
associated with the risk of VTE (data unpublished). Remarkably in this analysis no signifi-
cant association of VTE and SNPs within the coagulation or prothrombotic pathways was 
found. This suggests that VTE risk in multiple myeloma patients is mediated by alternative 
mechanisms, such as response to DNA damage and cytokine mediated apoptosis. In the 
same study it was shown that there are a limited number of SNPs, that can predict the risk 
of VTE, when analysed together. However this should first be validated in large prospective 
clinical trials(58). Future studies using global coagulation tests and studies on genetic fac-
tors that predispose for VTE will further unravel the pathogenesis of venous thrombosis in 
patients with multiple myeloma. This may be helpful in predicting which patients are most 
susceptible to develop a VTE complication during combination chemotherapeutic regimens. 
In turn this may lead to more appropriate antithrombotic prophylaxis to prevent VTE. 
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 Het multiple myeloom is een maligne plasmacel aandoening van het beenmerg en 
vormt ongeveer 1% van alle maligniteiten en 10% van de hematologische maligniteiten. 
Patienten met een multiple myeloom hebben een hoge incidentie van veneuze trom-
bose, die varieert tussen de 2% en 29%. Opvallend genoeg worden de meeste veneuze 
thrombotische complicaties gezien in de eerste maanden van behandeling, met name 
bij antracycline bevattende chemotherapie in combinatie met angiogenese remmers. 
Algemene factoren waarvan bekend zijn dat deze een belangrijke rol spelen bij het ontstaan van 
veneuze trombose zijn onder andere hoge leeftijd, immobilisatie, chirurgische ingrepen, infec-
ties en de aanwezigheid van een een centraal veneuze lijn. Over mogelijke stollingsafwijkingen 
die een pathofysiologische rol kunnen spelen bij de verhoogde thrombose neiging bij patiënten 
 met een multiple myeloom is nog weinig bekend. Recent onderzoek heeft aangetoond 
dat verworven afwijkingen, zoals resistentie tegen geactiveerd proteine C en een verhoogd 
factor VIII, kunnen optreden. De studies beschreven in dit proefschrift zijn verricht om meer 
inzicht te krijgen in afwijkingen in het stollingsmechanisme bij het multiple myeloom en in 
de mogelijke rol van die afwijkingen bij het ontstaan van veneuze trombose. 
 In hoofdstuk 1 wordt een overzicht gegeven van de wetenschappelijke literatuur over de 
incidentie van thrombo-embolische complicaties bij patiënten met een multiple myeloom en 
de beschikbare kennis over de primaire en secundaire hemostase bij patiënten met een mul-
tiple myeloom. Hiernaast wordt kort ingegaan op thromboprophylactische mogelijkheden 
 ter reductie van de thrombose incidentie. 
 In hoofdstuk 2 wordt een een studie beschreven naar afwijkingen in het stollingsme-
chanisme in een groep van 135 patienten met een onbehandeld multiple myeloom. Bij deze 
patiënten worden sterk verhoogde concentraties van factor VIII en von Willebrand Factor 
(vWF) gevonden. Deze waarden correleren sterk met het prognostische Internationale Sco-
rings Systeem (ISS), waarbij de hoogste concentraties van FVIII en vWF gezien worden in het 
hoogste stadium. Proteine S activiteit is gerelateerd aan het ISS stadium waarbij de laagste 
activiteit gemeten wordt in patiënten met het hoogste ISS stadium. Tijdens de behandeling 
met chemotherapie trad bij 10% van de patienten een thrombotische complicatie op. Er 
werd geen associatie gevonden tussen de afwijkingen in de stollingsparameters bij diagnose 
en het optreden van veneuze trombose. 
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 In hoofdstuk 3 wordt een studie beschreven waarbij stollingsonderzoek werd verricht 
voor de start van behandeling, na inductie chemotherapie en 3 tot 6 maanden na inten-
sieve behandeling met hoge dosis melphalan (HDM) gevolgd door autologe stamcel trans-
plantatie (ASCT) bij patiënten met een multiple myeloom. Factor VIII en vWF vertonen 
een parabolisch verloop met een significante stijging van de afwijkingen na de inductie 
chemotherapie. Na de intensieve behandeling dalen deze factoren tot onder de uitgangs-
waarde van voor de aanvang van behandeling. Dit verloop wordt bij elke vorm van inductie 
theapie gezien. Fibrinogeen stijgt ook tijdens de behandeling, en blijft vervolgens verhoogd 
na afsluiten van de intensieve behandeling met HDM en ASCT. In de patienten die be-
handeld worden met thalidomide in combinatie met adriamycine en dexamethason (TAD) 
vertoonde het fibrinogeen een significant hogere stijging ten opzichte van de patienten die 
vincristine in combinatie met adriamycine en dexamethason (VAD) kregen toegediend. De 
afwijkingen die werden gevonden tijdens en na behandeling waren niet geassocieerd met 
het ontstaan van veneuze trombose.
 In hoofstuk 4 is een onderzoek beschreven naar de fibrinolyse bij patiënten met een 
multiple myeloom. Recent onderzoek heeft aangetoond dat de kans op trombose is toege-
nomen bij individuen met een lage fibrinolytische capaciteit. De fibrinolytische capaciteit 
werd gemeten in plasma van 77 patienten met een multiple myeloom voor, tijdens en na 
inductie chemotherapie met VAD of TAD. De tijd die nodig is om een stolsel op te lossen 
(stolsel lysis tijd, clot lysis time) is voor de inductie therapie vergelijkbaar met gezonde 
controle personen. Tijdens de inductie chemotherapie verlengt de lysis tijd significant ten 
opzichte van die van de controle personen ten teken dat er sprake is van hypofibrinolyse 
tijdens de therapie. Na de intensieve behandeling met hoge dosis melphalan, gevolgd door 
autologe stamceltransplantatie daalt deze weer tot normaal. De verminderde fibrinolyti-
sche capaciteit, die ontstaat tijdens behandeling van patiënten met een multiple myeloom, 
kan bijdragen aan de verhoogde kans op veneuze trombose.
 Weefsel factor (Tissue Factor, TF) wordt gezien als de belangrijkste initiator van de stol-
ling. Eerder onderzoek heeft aangetoond dat er een associatie is tussen micro-partikel-
geassocieerde tissue factor activiteit (MP-TF) en het optreden van trombose bij patiënten 
met een adenocarcinoom. In hoofdstuk 5 wordt de plasma MP-TF activiteit gemeten zowel 
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voor als na inductie chemotherapie in 123 patienten met een multiple myeloom. Voor de 
inductie therapie is de MP-TF activiteit significant hoger dan in gezonde vrijwilligers (17.8 
fM Xa/min [IQR 8.8-32.8] versus 4.7 fM Xa/min [IQR 2.3-6.6], P<0.001). Er is geen relatie 
tussen MP-TF en de ernst van de ziekte, geclassificeerd met de Salmon en Durie criteria, 
noch met de prognostische ISS score. Na de inductie chemotherapie daalt de MP-TF acti-
viteit significant. Trombose werd gezien in 8% van de patienten behandeld met VAD, 11% 
van de patienten behandeld met TAD en 7% van de patienten behandeld met PAD. In de pa-
tienten die een trombose ontwikkelen bleef na inductie therapie de MP-TF activiteit hoog. 
MP-TF activiteit na inductie chemotherapie is significant geasscocieerd met het risico op 
trombose met een 4% stijging voor iedere unit van TF activiteit (95% CI 1-8%; p=0.03). Dit 
suggereert dat MP-TF activiteit een rol speelt in de ontwikkeling van trombose bij patienten 
met een multiple myeloom.
 Vanwege de hoge trombose incidentie, met name tijdens de inductie chemotherapie 
met thalidomide, is er momenteel veel aandacht voor medicamenteuze trombose profylaxe 
bij deze patientengroep. Bij multiple myeloom patienten die behandeled worden met che-
motherapie in combinatie met thalidomide worden trombose incidenties tot 29% gemeld. 
In hoofstuk 6 wordt het effect van laag moleculair gewichts heparine (LMWH) bestudeert 
op de trombose incidentie. In een groep van 412 patienten met een multiple myeloom 
die inductie chemotherapie kregen met TAD, werd tromboprofylaxe met LMWH toegepast. 
De incidentie van trombose bij de VAD patienten was 5% en bij de TAD patienten 10%. 
Deze studie toont aan dat toediening van LMWH aan patiënten met multiple myeloom, die 
chemotherapie in combinatie met thalidomide krijgen veilig is en de trombose incidentie 
reduceert. 
 In hoofdstuk 7 werden verschillende stollingsparameters onderzocht bij patienten met 
andere vormen van plasmacel ziektes, zoals monoclonale gammopathie of undetermined 
significance (MGUS), AL-amyloidose en de ziekte van Waldenström. Factor VIII en vWF zijn 
ook bij deze patienten duidelijk verhoogd, waarbij de hoogste concentraties gemeten wor-
den in de patienten met AL-amyloidose. De concentratie van proteine S is bij alle vormen 
van plasmacel ziektes verlaagd, terwijl het fibrinogeen gehalte bij de patienten met AL amy-
loidose significant hoger is ten opzichte van de andere plasmacel aandoeningen. Geconclu-
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deerd kan worden dat bij andere plasmacel aandoeningen vergelijkbare stollingsafwijkingen 
worden gevonden, als bij het multiple myeloom.
 In hoofdstuk 8 wordt een patient beschreven die bekend is met een erfelijke type 2A 
von Willebrand ziekte, die een multiple myeloom krijgt. In het plasma van deze patient werd 
een sterke stijging van het factor VIII en vWF gezien tov eerdere metingen. Dit leidde tot 
een vermindering van zijn pre-existente bloedings neiging. De behandeling van het multiple 
myeloom resulteerde in een daling van factor VIII en vWF. Hierbij ontstonden ook weer 
klachten van een verhoogde bloedingsneiging.
 In hoofdstuk 9 wordt een patiente beschreven met een therapie resistente leuko-
cytoclastische vasculitis ten gevolge van een MGUS. Deze patiente werd behandeld met 
frequente plasmaferese, waarbij Hydroxyethyl zetmeel (HES) werd toegediend ter vervan-
ging van plasma. Door de frequente plasmafereses werd HES in grote hoeveelheden aan de 
patiente toegediend. Deze patiente ontwikkelde vervolgens een ernstige stapelingsziekte, 
waarbij diverse weefsels massaal geinfiltreerd waren met geactiveerde schuimachtige ma-
crofagen. Aanvullend werd een onderzoek verricht naar mogelijke HES stapeling bij andere 
patiënten die eveneens frequente plasmafereses hadden ondergaan met HES als substi-
tutie. De met HES beladen schuimmacrofagen produceren het enzym chitotriosidase. De 
concentratie van dit enzym, gemeten in het bloed, kan gebruikt worden om de ernst van de 
stapelingsziekte te meten. Uitgebreide analyse van een groep van 12 patienten laat zien dat 
met name bij patienten met een pre-existente nierfunctie stoornis, de toediening van dit 
product leidt tot stapeling van HES, hetgeen tot uiting komt in een stijging van het enzym 
chitotriosidase. 
 hoofdstuk 10 bevat tenslotten een algemene samenvatting en discussie waarin de 
resultaten van dit proefschrift worden samengevat en bediscussieerd in het licht van recent 
ander onderzoek en de huidige inzichten. 
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 Velen hebben voor mij in de afgelopen 4 jaar een belangrijke rol gespeeld en op die wijze 
zowel indirect als direct hun bijdrage geleverd aan het tot stand komen van dit proefschrift. 
Ik zou graag een aantal persoonlijk willen bedanken, wetende dat hen die ik niet noem, voor 
mij een even belangrijke rol hebben gespeeld.
 pieter sonneveld. Beste Pieter. In 2004 werden de eerste officiele stappen ondernomen 
en afspraken gemaakt welke zouden moeten leiden tot dit proefschrift. De hierop volgende 
jaren hebben zich gekenmerkt door onrustige momenten waaroor het soms leek alsof het 
onderzoek stil kwam te staan. Jij toonde geduld en gaf mij de ruimte om, met wisselende 
pauzes, toch dit onderzoek af te ronden. Hiervoor ben ik je veel dank verschuldigd en kan ik 
alleen maar zeggen; soms moet je even stil staan om verder te komen. Ik heb je leren kennen 
als een plezierig en kritische begeleider van weinig woorden.
 frank leebeek. Beste Frank. Ik heb je leren kennen toen ik als assistent op de afdeling 
interne begon. Je zat toen in de laatste fase van het perifere deel van je opleiding. Je maakte 
toen al veel indruk door, met enige regelmaat, de opleiders te imponeren met jouw kennis 
over de stolling. Het was voor mij dan ook een plezierige samenloop van omstandigheden 
dat ik dit onderzoek onder de directe supervisie van jou heb mogen verrichten. Jij bezit veel 
kennis, verpakt in een grote hoeveelheid humor en geduld. Wat Zoro met zijn sabel kan, kan 
jij met de rode pen. Gelukkig werden de manuscripten er alleen maar beter van dus kon ik 
de pijn van het neersabelen goed verdragen. Ik heb de avonden dat ik even langs kon komen 
voor een maaltijd, bereid door jullie oppas, gevolgd door “hard werken aan het artikel”, als 
plezierig ervaren en ik meen het als ik zeg dat ik het jammer vind dat hier onze wetenschap-
pelijke wegen scheiden. Ik heb veel respect voor je en mijn dank is groot.
 prof.dr. d. poldermans. Beste Don. Mijn eerste klinische schreden het ik gezet op de 
afdeling chirurgie (heel lang geleden). Het is daar dat ik je heb leren kennen. Jij zag overal de 
humor van in en kon ook nog een aardig balletje tikken met je hockeystick. Ik weet nog dat 
je je verbaasde over het feit dat een assistent chirurgie de diagnose decompensatio cordis 
kon stellen, maar toen wist ik ook al dat mijn roeping elders lag. Onze wegen zijn uit elkaar 
gegaan toen ik “overliep” maar ik moet zeggen dat ik het ongelooflijk leuk vind dat je nu in 
mijn kleine commissie zitting hebt willen nemen.
151
D
ankw
oord
 prof.dr. J. lindemans. Beste Jan. Ik heb je pas sinds kort leren kennen en onze eerste 
kennismaking was voor mij zeer prikkelend. Ik heb het gevoel dat er nog veel onontgonnen 
terrein ligt op het gebied van vitamine B12 problematiek. Misschien dat ik in de polder daar 
wat meer aandacht aan schenken...
 henk lokhorst. Beste Henk. Bij de eerste stappen die gezet werden voor dit onderzoek 
was ook jij aanwezig. Een deel van mijn onderzoek heeft dan ook onder jouw vleugels mo-
gen plaats vinden. Ik heb je leren kennen als een integer en bescheiden persoon voorzien 
van goede sociale vaardigheden en veel kennis. Je bent standvast en dat waardeer ik erg in 
je. 
 Joost & bart & Job. Beste Daltons van mij. Joost, jij bent iemand die alles ziet maar niks 
zegt. Je hebt een fijn en eerlijk karacter en ik geloof je blind. Als jij iets zegt dan is dat ook zo, 
punt uit. Bart, jij zegt meer dan dat je ziet. Jij bent nergens bang voor en bent gewoon een 
doener. Dat er hier en daar wat vonken afspringen hoort gewoon bij jou. Job, jij bent mijn 
clown. Zo jong als jij bent weet jij met je guitige oogjes de wereld voor je te winnen. Soms 
sta ik echt versteld van wat je aan wijsheid zegt. Alle drie, jullie zijn mijn echte “Angels” en 
ik ben trots dat ik jullie vader mag zijn.
 pap & mam. Jullie hebben mij in mijn jeugd een rustige en stabiele thuishaven gegeven. 
Een veilige plek waar ik altijd welkom was en kon schuilen voor de stormen. Mijn vertrek 
naar Nederland voor de studie was voor mij een sprong in het diepe en ik denk dat ik rede-
lijk op mijn benen terecht ben gekomen. De fysieke afstand die ontstond door mijn vertrek, 
leek groot maar bleek eigenlijk slechts een kleinigheid te zijn. Jullie onvoorwaardelijke steun 
en vertrouwen hebben mij ongelooflijk geholpen. Ik hoop dat het voltooien van dit proef-
schrift een uiting van mijn dank aan jullie zal zijn. 
 peter & biekel auwerda. Hey bro en sis. Het is heel byzonder dat wij, na zo lang, weer 
een keer met ons 5-ven bij elkaar kunnen zijn. Brother, Toen ik ging studeren zat jij al in 
Rotterdam. Jij deed economie en ik medicijnen. Ik was toen en ben nog steeds trots op je 
en koester de herinneringen. Jij hebt een ongetemde honger voor kennis en spirituele aan-
gelegenheden. Sis, jij bent nuchter, kort van stof en niet klein te krijgen. We zien elkaar heel 
weinig maar als we elkaar zien is het net alsof ik nooit weg ben geweest. Ik heb echt respect 
voor de wijze waarop je je staande houdt en ben trots dat jij mijn sister bent. Tof dat jullie 
er bij zullen zijn.
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 Victor coenen. Best Vic. Ik heb je pas echt leren kennen tijdens onze rondreis door 
schotland. Het was prachtig winters weer en we hebben het geheim van de “Angels” ontra-
feld. How much can Angels drink? Given the time, a lot! Vic, jij bent een “one in a million”. 
Sociaal ben je ongelooflijk vaardig, Golft een aardig balletje en bent internationaal bekend 
om je postzegelverzameling. Ik ken maar weinig visionairs maar jij bent er een van. Zonder 
jou zou ik hier nu niet kunnen staan. Ik vind het een eer dat je mijn paranymf wilt zijn en 
ben je dankbaar voor alles.
 Jan-pieter Klaver. Beste JP. Samen met Sophieke vormen jullie een ijzersterk team en 
zijn jullie in staat onrustige vaarwateren zonder enig probleem te trotseren (letterlijk en 
figuurlijk). Ik heb veel rust gevonden tijdens onze zeiltrips rond Mallorca en Menorca maar ik 
moet eerlijk zeggen dat je timing soms wel heel erg krap is. JP, ik ken jou als een nuchter en 
analytisch persoon en ook jij bent in mijn ogen een echte visionair. Met Vic en jou aan mijn 
zijde durf ik wel mijn boekje voor de commissie te verdedigen.
 francine & dick schot. Beste scorpio. Jij hebt de afgelopen jaren getoond een waardig 
vriendin te zijn met een nuchtere kijk op het leven. Ik dacht dat er niemand meer was die mij 
kon verrassen totdat ik moest verjaren. Wat gaat de tijd toch snel he. Ik ben je erg dankbaar 
voor je onvoorwaardelijke vriendschap. Ps; zorg goed voor mijn Nessie! Dick. Jij bent iemand 
van weinig woorden maar veel daden. De lay-out van dit boekje is aan jou te danken. Iets 
waar ik trots op ben. Je houdt niet van half werk en staat voor wat je zegt. Fijn dat ik je tot 
mijn vriendenkring mag rekenen. 
  Wil dijkers. Beste Wil. Jij hebt aan de basis gestaan van mijn opleiding tot internist. Als 
belangrijke schakel was jij onmisbaar en als een spin in een web had jij altijd alle touwtjes 
in handen. Je bent een belangrijke steun geweest voor mij en daar ben ik je dankbaar voor. 
Ook al kruisen onze wegen elkaar niet meer, toch blijf je mij, met een onzichtbaar draadje, 
op afstand binden. 
 Ad dees. Beste Ad. Fred Stadler heeft mij wel eens toevertrouwd, onder het genot van 
een fisherman, dat jij een belangrijke rol gespeeld hebt om mij de opleiding in te krijgen. 
Ik ken je als een eerlijk persoon met visie, die nooit teveel maar zeker ook nooit te weinig 
woorden gebruikt. Ik ben je dankbaar voor de tijd die ik samen met jou heb mogen werken 
en ik hoop dat het voltooien van dit boekje mijn dank enigzins kan onderstrepen.
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CURRICULUM VITAE
 De auteur van dit proefschrift werd geboren op 26 maart 1963 te Gouda. Zijn jeugd 
bracht hij door op Aruba alwaar hij het VWO-diploma behaalde aan het Colegio Arubano. In 
1982 werd gestart met de studie geneeskunde aan de Erasmus Universiteit te Rotterdam. 
In de laatste fase van zijn doctoraal liep hij onderandere stage in Hongarije en Kenia en in 
1987 behaalde hij het doctoraal examen. Het arts examen werd afgerond in 1989 waarna 
hij aansluitend werkte als officier arts bij de Koninklijke Marine te Den Helder aan boord 
van de Philips van Almonde en op de Centrale Ziekenboeg. Vervolgens werkte hij, eerst 
als onderzoeker en later als assistent, op de afdeling Chirurgie in het Erasmus Universitair 
Medisch Centrum te Rotterdam. In 1996 werd gestart met de opleiding tot internist in 
Rotterdam (Ikazia Ziekenhuis, Medisch Centrum Rijmond Zuid en het Erasmus Universitair 
Medisch Centrum). In 2001 starte hij met de opleiding tot hematoloog (opleider Prof.dr. 
B. Löwenberg). In 2002 behaalde hij een oorkonde op de Nederlandse Internisten dagen 
met het onderzoek waarvan hoofstuk 9 een stille getuige is. In 2003 behaalde hij zijn aan-
tekening tot hematoloog. Gedurende de laatste fase van de opleiding werd een aanvang 
gemaakt met het in dit proefschrift beschreven onderzoek. Gedurende 2003 - 2007 was hij 
werkzaam als internist-hematoloog in het Ikazia ziekenhuis te Rotterdam. Vervolgens was 
hij een periode waarnemend internist-hematoloog in het Meander Medisch Centrum te 
Amersfoort. Vanaf 2008 is hij werkzaam als internist-hematoloog in het Zuiderzee zieken-
huis te Lelystad. Naast algemene interne geneeskunde en hematologie verricht hij tevens 
diagnostische endoscopieen. 
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bbreviations
ABBREVIATIONS
ACA anticardiolipin antibodies
AL amyloidosis
ALSD acquired lysosomal storage disease
APA antiphospholipid antibodies
APC activated protein C
ASCT autologous stem cell transplantation
CAD cyclophosphamin, adriamycin and dexamethasone
CT chitotriosidase
DVT deep vein thrombosis
FVIII factor VIII
GD gaucher’s disease
HDM high dose melphalan
HES Hydroxy-ethyl starch
IL-6 interleukin-6
ISS International Staging System
LAC lupus anticoagulant
LMWH low molecular weight heparin
MGUS monoclonal gammopathy of uncertain significance
MM multiple myeloma
MNC’s mononuclear cells
MP melphalan and prednisone
MPS mononuclear phagocyte system
MP-TF microparticle tissue factor
PAD bortezomib, doxorubicin and dexamethasone
PAI-1 plasminogen activator inhibitor type I
PB-MNC’s peripheral mononuclear cells
PCD plasma cell disorders
PE pulmonary embolism
TAD thalidomide, doxorubicin and dexamethasone
TP tissue factor
t-PA tissue plasminogen activator
ULVWF ultra large von Willebrand Factor
VAD vincristine, doxorubicin and dexamethasone
VTE venous thromboembolism
VWF von Willebrand Factor
VWF:Ag von Willebrand Factor antigen
VWF:Cb von Willebrand Factor collagen binding activity
VWF:RCo von Willebrand Factor ristocitin cofactor
WM Waldenström’s macroglobulinemia
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